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Many gram positive bacteria, such as Mycobacterium tuberculosis, lack the redox protective 
molecule, glutathione and produce mycothiol (MSH) and ergothioneine (ESH) as their 
principal low molecular mass thiol instead. Ergothioneine has been known for a while as an 
anti-oxidant; however its role as a protective thiol in Mycobacterium tuberculosis is still 
undefined. Present knowledge indicates that ergothioneine may play a critical role in the in 
vivo and in vitro survival of Mycobacteria, hence enzymes involved in ESH synthesis can be 
considered as potential drug targets.   
Ergothioneine is synthesized by the sequential action of five enzymes, encoded by the genes 
egtA, egtB, egtC, egtD and egtE. Three of these enzymes implicated in the ergothioneine 
synthesis have been expressed and purified. The last step catalyzed by EgtE, a pyridoxal 5-
phosphate (PLP)-dependent β-lyase convert the S-(β-amino-β-carboxyethyl) ergothioneine 
sulfoxide to ergothioneine. This thesis describes the synthesis of ESH pathway enzyme 
substrates, with the main focus on the synthesis of the EgtE enzyme substrate, ESH 
biosynthetic precursor, R- and S-(β-amino-β-carboxyethyl) ergothioneine sulfoxide. In order 
to prove that synthesized compounds are indeed mycobacterium ESH pathway enzyme 
substrates, crude M. smeg cell free lysate enzyme was used to convert substrates to ESH. 
Enzymatic transformation was followed by LCMS analysis. 
One of two synthetic routes studied, required sufficient quantities of ESH and were therefore 
thoroughly reviewed. An improved synthetic procedure for ESH was obtained.  
Deuterated hercynine and ESH was prepared, which will serve as a valuable internal 
standards and probes for ergothioneine metabolic studies. Enantioselective sulfoxidation of 
EgtE enzyme substrate precursor, hercynyl cysteine sulfide gave the required hercynyl 
cysteine sulfoxide derivative and in same cases the hercynyl cysteine sulfone. Crude enzyme 
mediated transformation of substrates indicated that the hercynyl cysteine sulfide undergoes 
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Chapter 1 Introduction 
1.1. Tuberculosis 
Tuberculosis (TB) is a global infectious disease caused by the pathogenic gram positive 
bacterium Mycobacterium tuberculosis.1 Despite the availability of chemotherapy for many 
decades, tuberculosis remains a major global threat and a leading cause of mortality in the 
developing world.2  
1.2. The burden of disease caused by tuberculosis  
The disease was declared by World Health Organisation (WHO) as a global health 
emergency in 1993; however the rapid growth of the global population, the deterioration of 
the living conditions within developing countries and the spread of HIV drastically affected 
the magnitude of tuberculosis problem.  
Tuberculosis kills one person every 10 seconds,3 each year 1% of the global population is 
infected and an estimated one billion more people will be infected and 700 million killed by 
2020. In 2010 most of cases of TB occurred in Asia (57%) and Africa (26%), but a smaller 
incidence of TB has occurred in Eastern Mediterranean countries (7%), Europe (5%) and 
America (3%). 4 According to WHO (2010 statistics) the five countries with the highest TB 
incidence were India (2.0-2.5 million), China (0.9 million-1.2 million), South Africa (0.40 
million – 0.59 million), Indonesia (0.37 million – 0.54 million) and Pakistan (0.33 million – 
0.48 million) as shown in Figure 1.1.  
 

















According to statistics released by WHO in October 2011, there were an estimated 8.8 
million cases of TB reported globally in 2010, 1.1 million deaths amongst them 0.35 millions 
were HIV positive.4 Africa still has the highest reported incidence of TB patients co-infected 
with HIV, an overall 82 % was estimated (Figure 1.2). 
 
Figure 1.2.  Estimated HIV prevalence in new TB cases, WHO, 2010.5 
1.3. Mycobacterium tuberculosis (M. tb) 
Mycobacterium tuberculosis (M. tb) (Figure 1.3) has been found to mainly cause disease in 
humans. M. tb is a rod shaped bacterium, 2-4 µm long and 0.2-0.5 µm wide. It is an obligate 
aerobic pathogen, for this reason usually found in the lung in particular the well aerated parts. 
M.tb is a facultative intracellular parasite that has a very slow growth rate; it divides every 
15-20 hours which is a physiological characteristic that may contribute to its virulence. 
M. tb is classified as acid-fast bacteria due to the structure of its cell wall containing 
peptidoglycan although rich in lipids (over 60%). The cells wall consists of three 


















Figure 1.3 Mycobacterium tuberculosis scanning electron micrograph.6 
1.4. Drug treatment against tuberculosis 
The treatment of tuberculosis is difficult due to two major factors, persistence (survival of M. 
tuberculosis despite the use of antibiotics) and complete resistance. Because of the 
persistence of M .tb, drug treatment is extended between 6-9 months and even requires a 
combination of at least 3 effective drugs to cure the patients completely and prevent relapse.3 
In year 2000, an estimated 3.2% of all TB cases were multi-drug resistant. The resistance is 
due to a genetic mutation resulting in altered affinity of the target or the activator of the drug. 
Multidrug-resistant strains (MDR) are resistant to first line drugs; isoniazid (INH) and 
rifampicin (RFP), other strains carry even a greater level of drug resistance, called 
extensively drug-resistant (XDR) displaying resistance to fluoroquinolones and at least one of 
the injectable antibiotics (streptomycin, kanamycin, capreomycin) (Figure 1.4).7  
 

















The second and third-line TB drugs are less effective, more toxic, and more expensive than 
the first line drugs.  It is necessary to revert to 2nd line drugs when the patient either does not 
respond to the first line or does not tolerate them. Understanding the M. tb mechanism of 
defence (detoxification / xenotification) is an alternative approach to battle the disease 
(Figure 1.5). 
 
Figure 1.5 Structures of some examples of third-line TB drugs 
1.5. Challenges in tuberculosis drug discovery. 
TB treatment faces many problems, high cost and very long (6 to 9 months) treatment.  
Resistance of M. tb toward current drugs, toxicity, and TB / HIV co-infection etc, warrants 
the development of new more efficient, safe and affordable drugs.  
Existent TB drugs possess various mechanisms of action. The first-line antitubercular drug, 
isoniazid (INH) inhibits mycolic acid biosynthesis, one of the essential components of the 
mycobacterial wall cell. Pyrazinamide, which is structurally similar to INH, is a prodrug that 

















Rifampicin, acts on replicating and non-replicating mycobacteria by inhibiting bacterial RNA 
synthesis through binding to the β-subunit of the DNA-dependent polymerase.8, 9 
In the last decade, many promising drug candidates have entered clinical trials. These efforts 
gave rise to the fluoroquinolones; gatifloxacin and moxifloxacin (phase 3), oxazolidinone 
linezolid and nitroimidazole metronidazole (phase 2) have been repurposed for tuberculosis 
treatment. New chemical entities have also progressed in clinical development based on the 
optimization of known chemical scaffolds such as nitro-imidazole derivatives 
(oxazolidinones) and diaryquinolines (a new class of antitubercular drug).8 
Most of the abovementioned drugs target the cell wall; hence they are more susceptible to 
develop resistance. Therefore, modern drug discovery programs targets the metabolome, in 
search of essential metabolites. Low molecular thiols are metabolites that play a key role in 
maintaining a redox balance in mycobacteria and are responsible for the survival of M. tb.10 
The future of TB drug discovery is promisisng. Researches toward funding new biological 
targets, funding analogues of existing drug more effective and less toxic, disturbing the redox 
homeostasis of M. tb by inhibiting its protective anti oxidant thiol (MSH, ESH), as well as 
improvement of method of screening and testing of drugs candidates, etc are leading the 
future of TB drug discovery, 9, 11 as summarised in Figure 1.6. 
 

















1.6. Low Molecular Weight (LMW) thiols  
Low Molecular Weight (LMW) thiols play an essential role in the survival of many 
pathogenic microorganisms, acting as redox buffers, maintaining the redox homeostasis 
within the cells,12 and can defend the cells from damage inflicted by reactive oxygen and 
nitrogen species13 (Figure 1.7) 
 

















The principal thiol in most organisms (eukaryote and gram negative bacteria) including 
human is glutathione (GSH), a cysteine-based thiol. Most gram positive bacteria lack GSH, 
but produce a range of alternate LMW thiols. Trypanosoma and Leishmania produce 
trypanothione (TSH) and ovothiols (OSHA, B & C) which belong to the cysteine and mercapto-
histidine based thiol classes respectively. Bacilithiol (BSH) and co-enzyme A (CoA), also 
both cysteine based thiols were established to act as protective thiols in Bacillus and 
Staphylococcus.15, 16 
Many gram-positive bacteria like Staphylococcus aureus do not produce GSH; instead they 
do rely on CoA as their principal protective thiol. It has been shown that Staphylococcus 
aureus produces millimolar levels of reduced CoA, a unique redox thiol / disulfide redox 
system.17 
Interest in CoA is growing, searching for antibiotics capable to kill Staphylococcus aureus, 
the agent causal of nosocomial infections. Research toward finding effective therapy against 
MRSA (Methyllicin multi-drug Resistance strains of Staphylococcus aureus) is still big 
challenge and CoA, the protective unique thiol of S. aureus, emerges as the new potential 
drug target.48 
Very recently due to emergence of multi drug resistant M. tb strains (XDR) against TB drug, 
targeting the CoA pathway appear to be promising in TB drug discovery.19 
1.6.1. Trypanothione (TSH). 
TSH was identified in trypanosomatids, the causal agent of sleeping sickness, in the 1980s. 
TSH consists of 2 molecules of GSH linked covalently to spermidine.20 In trypanosoma cruzi 
the concentration of T(SH)2 depends on the parasite life stage, about 1.5-2.1 mM in 
epimastigotes cultured in presence of polyamines, 0.5 mM in trypomastigotes and 0.12 mM 



















Figure 1.8 Biosynthesis of  T(SH)2 .20 
1.6.2. Sleeping sickness and drug discovery based on the TSH biosynthesis pathway  
Sleeping sickness, called also Human African Trypanosomiasis (HAT), is one the most 
neglected diseases, because it affects the poorest of African populations, making any drug 
development economically unattractive for pharmaceutical industries.21, 22 
It is caused by unicellular flagellated parasite subspecies Trypanosoma bruccei, transmitted 
in Africa via an infected tsetse fly. Clinically there are two forms of diseases, the first known 
as West African sleeping disease, chronic disease caused by T. gambiense. Although the 
second form, known as East Africa sleeping disease, is caused by T. rhodesiense, which is 
more virulent and endemic in East and Central Africa.22, 23 
For over 50 years, chemotherapy of sleeping sickness disease has evolved and currently there 
are five drugs widely used against HAT, depending on the stage of the disease. These drugs 
include; suramin, pentamidine, melasorprol, nifurtimox and difluoromethylornithine (Figure 
1.9). In comparison to all available drugs, the most efficacious of all are 
difluoromethylornithine (DFMO). This is the only example of a successful, clinically 
available, mechanism-based inhibitor across the spectrum of species of LMW thiol producing 


















Figure 1.9 Current Drugs against HAT.21 
DFMO irreversibly inhibit ornithine decarboxylase (ODC), a PLP-dependent enzyme 
implicated in the first step of the biosynthesis of polyamines (Figure 1.10).  
 

















1.6.3. Bacillithiol (BSH) 
BSH was isolated by treating Deinococcus radiodurans cell extracts with monobromobimane 
(mBBr) and its structure was elucidated as the corresponding fluorescently labelled S-bimane 
derivate (BSmB) (Figure 1.11).  
 
Figure 1.11 Structure of Bacilithiol-S-Bimane.24 
It has since been found that BSH plays an important role in many metabolic regulation 
processes including sporulation, acid and salt resistance and detoxification of electrophilic 
xenobiotics such as fosfomycin.24 
The interest in BSH is still growing due to the fact that BSH occurs in several clinically 
important pathogens like Bacillus anthracis, Bacillus cereus, Staphylococcus aureus, 
Staphylococcus saprophyticus and Staphylococcus agalactiae, all of which do not produce 
MSH or GSH. The biosynthesis and the first total synthesis of BSH were very recently 
established by Hamilton et al.25 
1.6.4. Mycothiol (MSH)  
Mycobacterium tuberculosis produces mycothiol (MSH) and ergothioneine (ESH) which 
belong to the cysteine and mercapto-histidine based thiol classes respectively. It has been 
established that MSH plays a crucial role in the growth and survival of M. tb.  
In M. tb, MSH function, as redox buffer, is involved in detoxification of electrophilic 
compounds such as alkylating agents and antibiotics. The latter occurs by means of 
conjugation and subsequent expulsion as a mercapturic acid.12, 13 The level of MSH in M. tb is 
still the highest (millimolar levels) observed, compared to any microorganism.14 MSH is 



















Figure 1.12 Biosynthesis of MSH.12 
Two enzymes, Mtr (mycothiol disulfide reductase) and Mca (mycothiol S-conjugate amidase) 
play the important end stage functional role in the MSH biosynthesis pathway (Figure 1.12). 
As mentioned before, these enzymes are responsible for redox homeostasis and detoxification 
respectively. 
Many studies were conducted on mycothiol biosynthesis in M. tb as well as M.smeg. mutants, 
bearing mutations of mshB and mshD resulting in the production of low levels of MSH, thus 
making these organisms more sensitive to oxidatives stress.13  
Efforts to clone Mycobacterium tuberculosis lacking mshA and mshC genes were 
unsuccessful, but recently, a Mycobacterial tuberculosis msh A mutant were isolated, 
suggesting that mshA, mshC and mtr (mycothiol reductase) genes are essential in M. tb. 
However, the bacteria can adapt to the lost of mycothiol presumeably due to the presence of 


















However after deleting mycothiol synthesis in vitro or in vivo, the M. tb still survives 
suggesting that the bacterium does have an alternative low molecular weight thiol (LMW), 
which compensate for the lost of mycothiol (MSH).   
Recently Fahey et al found a drastic increase of ergothioneine in MSH- deficient strains, 30 
fold for mshA strain and 20 fold for mshC strain, suggesting the effective up regulation. 
Despite numerous papers dealing with ergothioneine, its role in Mycobacteria is still not fully 
understood.13 
Mycothiol (MSH) and ergothioneine (ESH) are the principal small molecule thiols produced 
by M. tb. It was shown through specific deletion mutations of enzymes along the biosynthetic 
pathway of these small molecule thiols that such mutant bacteria are vulnerable to existing 
drugs.13 Thus, the enzymes involved in the biosynthesis of small molecule thiols can be 
considered as a novel targets for antitubercular drug discovery antitubercular drug. 
1.7. Redox homeostasis in mycobacteria. 
It has been known for more than a hundred years that M. tb is an obligate aerobe, although 
research has shown that M. tb can survive in vitro under anaerobic conditions for many 
decades.  
The redox balance in M. tb can be disturbed by many factors intra-or extracellularly, which 
allow the bacteria, through unknown mechanisms, to subvert the immune system and to cause 
TB. Isoniazid (INH), ethionamide (ETA) and the nitro-imidazole drug, PA-824, need 
bioreductive activation. Hence, a redox imbalance affects the efficacy of such TB drugs. 
Furthermore, studies demonstrated that the increase in the NADH / NAD+ ratio could also be 
responsible for INH resistance.26 Mycobacteria with deletion mutations in MSH biosynthesis 
demonstrated resistance to INH and ETA.27 However, the mechanism used by M. tb to 
maintain the redox homeostasis, their role in drug susceptibly and efficiency remain poorly 
understood. 
M. tb lack the GSH redox couple (GSSG / 2GSH) and instead contains the mycothiol redox 
couple (MSSM / 2MSH) as major redox buffer in millimolar quantities. Although its redox 
potential has not been determined, many studies are limited to determine the ratio of MSSM / 


















FAD-binding mycothione reductase catalyses the reduction of mycothiol disulfide using 
NADPH as a cofactor as depicted in equation (1) 
 
It has been proven that MSH deletion mutants are sensitive to oxidative stress caused by 
H2O2, cumene hydroperoxide and O2. –. 
The redox couple of ESH ox/ESH red (E
O = - 60 mV) and its role as protective thiol is not well 
known, however it has been shown to protect mammalian cells against oxidative stress.28 
Understanding the redox homeostasis in the mycobacteria and how it influences drug efficacy 
remains the key to control TB. Is MSH the major redox buffer in M. tb and what role does 
ESH play in the maintenance of redox homeostasis in M. tb and in disease progression?  
1.8. Mercaptohistidine based Low Molecular Weight Thiols  
Ergothioneine (ESH) and ovothiols (OSH A, B & C) belong to the mercaptohistidine based 
LMW class and they differ from each other by the position of –SH and the degree of N-
methylation of the amino acid. 
1.8.1. Ovothiols. 
Ovothiol or N-methyl S-thiohistidine contain a relatively acidic thiol group (pka = 1.4) (Figure 
1.13). Unlike ESH, ovothiol readily undergoes oxidation by H2O2 or atmospheric oxygen to 
form the disulfide. OSH was first isolated in the late 1970s from the eggs of S. purpuratus. 
Since then research were conducted to understand its biochemistry and biosynthesis. 
Recently, the discovery of OSH in pathogenic Trypanosoma and Leishmania, has raised the 
interest in trypanosomal drug discovery.29  
 

















OSH plays an important role as an anti-oxidant in the redox defence of a number of 
organisms. Marine organisms produce a high amount of OSH, for example sea urchin eggs 
contain several millimolar OSHC, required to protect eggs during oxidative envelope 
maturation.29, 30, 31 
1.8.2. Ergothioneine (ESH). 
ESH was first isolated by Tanret in 1909 from ergot (Claviceps purpurea), the fungal 
infection of rye grain. Since that discovery numerous studies has been conducted to 
understand its role as protecting thiol in mycobacteria. Although many hypotheses have been 
suggested, its natural function in M. tb cells is still not fully unravelled.  
1.8.2.1. Structure and distribution 
ESH is a histidine derivative (2-mercaptohistidine N,N,N-trimethyl betaine) with a thiol 
group attached to the C-2 position of the imidazole ring. ESH is an unique natural C2-thio-
imidazole containing amino acid.14 (Figure 1.14.) 
 
Figure 1.14 Structures of Ergothioneine (ESH). 
In aqueous solution the thiol form (III) is more abundant than the thione form (I), although at 
physiological pH (7.4), the thione form (I) appears to be predominant (Figure 1.15). 
 
Figure 1.15 Possible tautomeric structures of ESH 
This characteristic distinguishes ESH from other biological LMW thiols and explains the fact 
that ESH is stable and is not easily auto-oxidized unlike other alkylmercaptans.14, 32  
ESH is synthesized mostly by some bacteria and fungi in the soil at a level of 0-5 µmol per g 
and is easily absorbed by plants through the roots. The level of ESH has been measured in 
Actinoplanes philippinensis, Nocardia asteroides strains (Actinomycetes) and in three species 

















Animals as well as humans do not synthesize ESH; instead they acquire it from their diet.  
Foods rich in ESH include mushrooms, corn, oats and meat. ESH concentrates in specific 
tissues or cells such as erythrocytes, liver, kidney, central nervous system, heart, seminal 
fluids, red bloods cells and ocular tissues.34 It has been shown that the concentration of ESH 
in human red blood cells is 1.5- 3.7 mg/100 ml, while the human lens contains 68-115 
mg/100 g.35 
ESH protects spermatozoa against oxidative stress and confers to it viability during storage. It 
has displayed a critical protective role in seminal fluid as it is the predominant thiol 
compound in a human, pig and horse semen.36 
Recently, a cation transporter (OCTN1) with high substrate specificity for ESH has been 
discovered. OCTN1 is now established as the ESH transporter and is responsible for the non 
uniform distribution of ESH in different cells within the same species.   
1.8.2.4. Antioxidant activity  
It has been shown that ESH protects rats in vivo against hepatic injury (damage occurs 
through the formation of lipid peroxides). 37 ESH is widely used in cosmetics as an active UV 
protectant; it has been proven to block the formation of various reactive oxygen species 
including singlet molecular oxygen, superoxide, hydroxide radical, protecting then the skin 
against any form of UV damage (skin cancer). Amongst other thiols such cysteine, N-acetyl-
cysteine, glutathione, ESH emerges to be the most efficient UV skin protectant and offers ten 
fold greater protection than glutathione.32, 38 
1.8.2.3. Biosynthesis of ergothioneine 
The attempt to elucidate the biosynthesis of ergothioneine has started some decades ago. In 
1956, Heath et al elucidated ESH biosynthesis in Claviceps purpurea. He demonstrated that 
histidine or a compound closely related to histidine might be a precursor of ESH.39  
The same year, Melville et al investigated the ergothioneine biosynthesis pathway in 
Neurospora crassa, an organism selected for this study because of its high concentration in 
ergothioneine. Using the classical radio isotopic labelling (14 C and 35S) method, Melville et al 
found that histidine is the precursor for ergothioneine biosynthesis, the introduction of a 
sulfhydryl group is provided by cysteine, and at least one of the three methyl groups of 
ergothioneine is derived from methionine.40 The same year, Heath et al established that 

















In 1962, Melville et al published the biosynthetic sequence of ergothioneine biosynthesis, 
which involved histidine, thio-histidine and hercynine as intermediates whereby cysteine is 
the source of the introduced thiol to the imidazole moiety and methionine is responsible for 
the trimethylation of the amino acid moiety (Figure 1.16).40 
 
Figure 1.16 Ergothioneine biosynthesis sequence.30 
Five years after the Melville study, Genghof et al42 confirmed that endogenous hercynine is 
the ESH biosynthetic precursor in Mycobacterium smegmatis. They also found that the 
addition of cysteine in their preparation caused the formation of 100 to 200 µg of ESH per g 
of dry cells after only 2.5 to 3 hours of incubation, thus supporting that cysteine is the direct 
source of sulphur in M. smeg ESH.40, 42 
Recently, Seebeck was the first to publish the gene cluster (egtABCDE) encoding for ESH 
biosynthesis in Mycobacterium smegmatis (Figure 1.17). All these enzymes were examined 
but not studied in detail yet; EgtA was identified as a glutamyl cysteine synthetase, EgtB as a 
FGE (Formylglycine Generating Enzyme) like protein, EgtC as a glutamine 


















Figure 1.17 (Top) Mycobacterial ergothioneine gene cluster, (Bottom) Reaction sequence of ESH 
biosynthesis.43  
The biosynthesis started with the trimethylation of histidine (I) by a S-Adenosyl Methionine 
(SAM) dependent enzyme EgtD to form hercynine (II) as the first intermediate in the 
biosynthesis. The second step involved the condensation and oxidation of hercynine (I) with 
glutamyl cysteine, yielding glutamyl cysteine sulfoxide (III), catalyzed by an iron II 
dependent oxidase enzyme (EgtB). The latter enzyme could also catalyze the direct coupling 
of hercynine (II) and cysteine to form hercynyl cysteine sulfoxide (IV) as the second 
intermediate in the biosynthesis; this alternative route was previously suggested by Ishikawa 
et al.44 
Finally the last step is catalyzed by a PLP–dependent β-lyase enzyme EgtE, involved the 
cleavage of the sulfoxide intermediate (IV) to form ergothioneine (V). Seebeck et al 43 
expressed and characterized all the enzymes implicated in the pathway except EgtE because 
of an expressed protein solubility problem, a common problem for cofactor dependent 
enzymes of slow growing organisms.43 
Higher eukaryotes lack the genes for ESH biosynthesis, which is produced in a wide range of 
Actinobacteria, in particular Mycobacteria and therefore may represent a novel target for 



















1.9. Objectives of the study 
Very recently Bello et al 45 found that ESH is the major low molecular weight thiol in conidia 
of Ascomycetes C. graminicola and N. crassa. By using two strains of conidia, wild type and 
NcΔEgt-1 (conidia mutant lacking ESH), they demonstrated that endogenous ESH is 
responsible for the protection of plants against peroxide toxicity during the germination 
process.  
Unpublished work conducted by our collaborators Sao, C. and Baker B., University of 
Stellenbosch, Tygerberg, South Africa has highlighted that ESH is essential for the survival 
of M. smeg, as demonstrated by the increased sensitivity of ESH deficient mutants toward 
antitubercular drugs.   
Amongst all the ESH pathway enzymes, EgtE and EgtD implicated in the first and last step 
respectively, seem to be indispensable to the biosynthesis of ESH.  Based on these findings, 
the research in this thesis aims to: 
(i) Provide improved synthetic methods to produce significant amounts of EgtD and EgtE 
substrates in order to allow further investigation of the pathway enzymes, in 
particular EgtE, which is hitherto unavailable. 
(ii) In the absence of expression systems for EgtE, the groundwork for classical protein 
purification methods will be established utilising crude EgtE enzyme from 
Mycobacterial smegmatis. 
(iii) Establish LCMS methods to monitor conversion of EgtD and EgtE substrates to ESH 
using crude enzyme extracts from M. smegmatis 
(iv) Synthesize stable isotopically labelled substrates for metabolomic studies and drug 
discovery.  Ultimately, these tools will be used to develop a multiwell plate assay for 
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Chapter 2 Total synthesis of Ergothioneine 
2.1. Introduction 
ESH have been studied for almost a century as it has been detected in most plants and 
animals. Although its quantification in fresh tissues was hindered through lack of 
standardized methods of detection.1  
A range of submillimolar to millimolar concentrations of ESH has been found in the cornea, 
bone marrow and seminal fluid (where it is the highest level). ESH was also found in central 
nervous system and ranged from 0.36 to 0.03 mg/100gm depending on the brain region and 
type of animal examined.2, 3  
Due to increasing commercial interest, a scaleable synthetic process for L-ergothioneine is 
valuable. Research quantities is commercially available, but very expensive (5767. 98 ZAR 
per 25 mg Sigma Aldrich).4 ESH synthesis holds unique process challenges, despite its 
apparently simple structure, many procedures has been developed to date, but only three of 
the published methods emerged as efficient.  
2.2 Retrosynthetic Analysis 
The retrosynthesis leads to commercially available L-histidine that affords hercynine through 
N-methylation as well as thionation using different approaches depending on the nature of the 
sulfur sources utilized (Scheme 2.1). According to this strategy, thiation requires the 



















Scheme 2.1 Retrosynthetic strategy of L-ergothioneine synthesis. 
2.3. Synthesis of L-ergothioneine using the Yadan approach  
Yadan et al 5 published the first total synthesis of L-ergothioneine in five steps (Scheme 2.2).  
This synthesis starts by the esterification of the commercially available L-histidine (1) to 
obtain the L-histidine methyl ester (2), which was dimethylated via reductive amination 
affording the N, N-dimethyl histidine methyl ester (3).   
The key step of this synthesis is the thiation which was performed by reacting intermediate 
(3) with phenyl chlorothionoformate (PCTF) under basic conditions (NaHCO3). The sulfur 
and nitrogen of the imidazole ring of the N,N-dimethyl mercapto histidine (4) intermediate 
was protected by reacting it with ethyl chloroformate prior to quaternarization of the amine to 
afford N- and S-protected ergothioneine (6). Acid mediated deprotection yield the target, L-


















Scheme 2.2 Yadan ergothioneine Synthesis 5 reagent and conditions (a) MeOH, gaseous HCl; (b) 37 % 
aqueous CH2O, H2, 10 % Pd/C , rt; (c) (i). PCTF, NaHCO3, H2O / Et2O, (ii)  TEA, MeOH, rt (d) ClCO2Et, TEA, 
CH2Cl2, 10 °C; (e) MeI, THF , rt; (f) Conc HCl, 75 equiv HSCH2CH2CO2H  
According to the Yadan method L-ergothioneine was synthesized in 6 steps, used tedious 
chromatographic purification methods and resulted in a high degree of racemisation of the 
final product. The overall yield was low (34 %) and difficult to reproduce. 
This synthesis required the use of many toxic reagents such as thiophosgene (CSCl2) to 
synthesize PCTF in situ. This method also required the use of considerable amounts of 
halogenated organic solvent and concentrated hydrochloric acid, which generates a large 
amount of harmful waste for the environment.  
Considering all the disadvantages mentioned above, Trampota developed another synthetic 
route.  
2.4. Attempted synthesis of ergothioneine using the Trampota method 
A decade later, Trampota et al 6 patented the second total synthesis, similar to the Yadan 
method. The major improvement in this approach was the introduction of sulfur in the 
imidazole ring using KSCN via the Bamberger imidazole cleavage reaction, followed by t-

















After careful evaluation of the available synthetic procedures, it was decided to attempt the 
Trampota method. L-Ergothioneine was synthesized in 7 steps from commercially available 
histidine methyl ester (1) (Scheme 2.4). The Bamberger imidazole cleavage method gave in a 
number of sequences, subsequent intermediate, the (S)-2,3-diamino-4-oxopentanoic acid (4a) 
thiation using KSCN affords mercapto histidine (4), which was further transformed into 
ergothioneine (8) as outlined in the Scheme 2.3. The detailed report of this synthesis follows. 
 
Scheme 2.3 Synthesis of (8). Reagents and conditions: (i) NaHCO3,  BzCl / THF:H2O 10:90 18-24 h at rt (82%); 
(ii) MeOH / HCl 5 hr at rt (95.5%); (iii) a. HCl 15 h at 90-93°C; b. KSCN 4-5 hrs at 80-90°C (87.8%); (iv)  t-
BuOH / HCl reflux for 3-4 h (62.7%); (v) Formalin, sodium triacetoxyborohydride  / THF, 6-8 h at 10°C (33.7 
%); (vi) NH4OH, CH3I / MeOH  24 h at rt; (vii) HCl, 2-mercaptoprionic acid  refluxed for 21h (27.3 % over 2 
steps).  
2.4.1. Synthesis of (S, Z)-methyl 2, 4, 5-tris (benzamido) pent-4-enoate (2), the Bambeger 
imidazole cleavage. 
Commercially available histidine methyl ester dihydrochloride (1) was N-benzoylated using 
benzoyl chloride under basic conditions (NaHCO3) in a mixture of THF and H2O as a 
solvent. The reaction was monitored by TLC, showing complete disappearance of starting 
material after 24 hours. 


















Scheme 2.4 Synthesis of (2) : reagents and condition. NaHCO3,  BzCl / THF: H2O (10:90), 18-24 h at rt (82%)  
2.4.1.1. Mechanism of Bamberger imidazole cleavage. 
Bamberger et al 7 reported in 1893 that imidazole in the presence of an acylating agent such 
as an acyl chloride in an alkaline medium (NaHCO3 aq) and an inert solvent, underwent a 
hydrolytic ring cleavage to give a N,N-diamino acyl-substituted alkene.7 Since this discovery 
the reaction has found many applications in organic synthesis involving the preparation of 
1,2-diamino vicinal alkenes. It has also been used as a method of detection of imidazole and 
histidine components.  
Later, Pratt et al 8 and Avaera9 as well as Vliegenthart10 systematically investigated its 
mechanism and proved that the imidazole ring cleavage is possible under mild conditions. 
The mechanism involves the reaction of 3 mol equivalents of benzoyl chloride with the 
carboxylic acid ester (1) to form species (i), which is hydrated to form hydro imidazole (ii). 
The intermediate (ii) undergoes imidazole ring cleavage to yield (iii), finally deformylation of 
(iii) affords the N,N-diaminoacyl product (iv). At higher concentration of an acyl chloride, the 
rate-determining step was the breakdown of tetrahedral 2-hydroxy-4-imidazoline (ii) (scheme 
2.5). Pratt et al noted that it is possible to end up with a mixture of (iii) and (iv) in almost 
equal proportions, but performing the reaction at higher pH and much for longer time would 


















Scheme 2.5 Proposed mechanism of Bamberger imidazole cleavage.8 
2.4.1.2. Characterisation of Bamberger imidazole intermediate, the (S, Z)-methyl 2, 4, 5-
tris (benzamido) pent-4-enoate (2) 
Evidence for the formation of the Bamberger intermediate (2) was obtained by spectroscopic 
methods. The 1H NMR spectrum in CDCl3 displayed three distincts deshielded ortho sets of 
aromatic resonances integrating for two protons each and a multiplet in the aromatic region 
(δH 7.60 to 7.39 ppm) integrating for 9 protons (meta and para), thus confirming the 
introduction of two benzoyl-groups. All three NH protons were also established to be down 
field at δH 9.91 (d, J = 8.7 Hz, 1H, NH-7), δH 8.84 (s, 1H, NH) ppm in close proximity to two 
carbonyl groups. Hence the two NH protons were more deshielded one slightly shifted up 
field at δH 7.16 (d, J = 6.8 Hz, 1H, NH) ppm. The characteristic methyl ester resonated up 


















Figure 2.1 1H NMR spectrum of (2) in CDCl3 at 400 MHz 
The 13C NMR spectrum of the Bamberger intermediate (2) displayed four carbonyl signals, 
twelve aromatic resonances, displaying the introduction of three benzoyl groups, two vinyl 
resonances respectively at δC 115.8 to 115.0 ppm showing clearly that imidazole ring was 
cleaved, and the correct number of carbon resonances, thus confirming the carbon skeleton of 
product (2).  
In addition, the FTIR spectrum in KBr showed a diagnostic absorption band at 804 cm-1 
confirming the presence of the phenyl moiety and strong absorption band at 1671 cm-1 
proving the insertion of the benzoyl group.  
Finally the EI+ mass spectrum displayed a molecular ion at m/z 471.1 ([M+H])+ calculated for 
C27H26N3O5: 471.2 supporting the assigned structure of (2).  
2.4.2. Synthesis of (S, Z)-methyl 2,5-bis(benzamido)-4-hydroxypent-4-enoate (3b). 
This step required anhydrous HCl for the deaminative cleavage of one of the three benzamide 
groups of compound (2). Hence, HCl gas was prepared in situ in an ice cold water bath (0-

















hydrolysis of product (2) after 24 hours and the recovery of product (3) in an excellent yield 
of 95 % after recrystallization (Scheme 2.6).11, 12 
 
Scheme 2.6 Synthesis of (3) reagent and condition: MeOH / HCl 5 h at rt (95.5 %)  
Shinkwin et al13 showed in their report that the enol tautomer form of ethyl 4-
oxotetrahydrothiophene-3-carboxylate was the most predominant tautomer at equilibrium in 
chloroform-d3 and the only form visible in the 
1H NMR spectrum. This phenomenon was 
ascribed to the intramolecular hydrogen bonding that arises with an ester in its vicinity. 
Hence, this explains the presence of a singlet at δH 6.81 ppm which wasn’t coupling to any 
other proton suggesting fast proton delocalization between the methylene and ketone 
carbonyl (Scheme 2.7) and the appearance of OH signal as a broad singlet at δH 7.14 ppm.  
 
Scheme 2.7 Proposed tautomeric forms of (3) in equilibrium between (S)-methyl 2,5-bis(benzamido)-4-
oxopentanoate (3a) and (S,Z)-methyl 2,5-bis(benzamido)-4-hydroxypent-4-enoate (3b) 
Evidence for the formation (S, Z)-methyl 2,5-bis(benzamido)-4-hydroxypent-4-enoate (3b) 
was obtained by 1H NMR spectra analysis as well as EI-MS. The proton NMR revealed 10 
aromatic resonances, a multiplet in the aromatic region from δH 8.21 to 7.72 ppm integrating 

















protons (two meta and four para protons) compared to (2) which was revealed at about the 
same chemical shift, thus indicating the disappearance of one benzoyl ring. The methyl ester 
proton signal resonated as a singlet at δH 3.83 ppm and the methylene signal resonated as a 
multiplet, slightly shielded, at δH 2.95 ppm suggesting close proximity to the carbonyl group 
thus supporting the assigned structure of (3) (Figure 2.2).  
 
Figure 2.2. 1H NMR spectrum of (3b) in CDCl3  at 400 MHz 
The melting point of (3) was in agreement with that reported in the literature.6 Finally the EI+ 
mass spectrum displayed a molecular ion at m/z 367.8 calculated for C20H20N2O5: 368.1 
supporting the assigned structure of (3).  
2.4.3. Synthesis of 2(S)-2-amino-3-(2-mercapto-1H-imidazol-4-yl) propanoic acid (4) 
The (2S)-2-amino-3-(2-mercapto-1H-imidazol-4-yl) propanoic acid (4) was a key 
intermediate toward the synthesis of our target, because it only required N-methylation to get 
to the target, ergothioneine. The intermediate (4) was synthesized in two sequential steps. 
First, the acid hydrolysis of (3), yielding the formation of (2S)-2,5-diamino-4-oxopentanoic 
acid (4a) giving benzoic acid as a by product which was removed by filtration. The 
intermediate (4a) was used directly in the next step without further purification. Finally (4a) 

















of the mercapto imidazole ring. The product (4) was isolated as a white powder after freeze 
drying and in a good yield of 88 % (Scheme 2.8). 
 
Scheme 2.8 Synthesis of (4).reagent and condition (i) HCl 15 h at 90 - 93°C, (ii) KSCN 4 - 5 h at 80 - 90°C 
(88%) 
The 1H NMR spectrum of (2S)-2-amino-3-(2-mercapto-1H-imidazol-4-yl) propanoic acid (4) 
in deuterium oxide displayed a characteristic aromatic signal for proton H-5’ resonating as a 
singlet at δH 6.87 ppm indicative of the formation of the mercapto ring. Other keys signals 
were the α-amino acid proton H-2 resonating as a triplet at δH 4.31 (J = 6.6 Hz) ppm, 
suggesting coupling with the neighbouring methylene protons, and a set of two doublet of 
doublets resonances at δH 3.28 (J = 16.1, 6.6 Hz) and δH 3.17 (J = 16.1, 6.6 Hz)  for proton H-
3a and H-3b respectively, confirming the presence of an amino acid moiety. The NH, OH, 
and SH protons were not observed in the spectrum, presumably all exchanged with deuterium 
as D2O was used as NMR solvent (Figure 2.3).  
 

















The 13C NMR spectrum of compound (4) (Figure 2.4) displayed six carbon resonances, 
supporting the carbon skeleton of L-mercaptohistidine (4). In addition, the melting point was 
recorded as 206-208°C (with decomposition) which was in agreement with that which was 
reported by Harington et al.14 
 
Figure 2.4 13C NMR spectrum of (4) in D2O + DCl  at 400 MHz 
The FTIR spectrum in KBr showed a strong absorption at 2073 cm-1, characteristic of a 
mercapto band (N=C-SH) proving successful thiation. Strong absorption at 3465, 1634 and 
1129 cm-1 indicated the presence of a free amine, while a medium absorption at 1383 cm-1 
indicated the presence of a carboxylate ion which strongly supported the assigned structure of 
(4). Finally the EI+ mass spectrum didn’t display the molecular ion peak, instead it revealed 
the sodium adduct at m/z 209.0 confirming the assigned structure of (4).  
2.4.4. Synthesis of (S)-2-amino-3-(2-(tert-butylthio)-1H-imidazol-4-yl) propanoic acid (5) 
In order to protect the integrity of the mercapto imidazole ring and to proceed to a regio 
selective N-alkylation, the sulfur atom was protected by a tert-butyl group prior to the 

















Compound (5) was obtained by refluxing 2.6 mol equivalents of t-butanol and (2S)-2-amino-
3-(2-mercapto-1H-imidazol-4-yl) propanoic acid (4) in distilled H2O containing HCl as a 
catalyst (to limit by product formation) for 4 hours. The protected thiohistidine (5) was 
isolated in a moderate yield of 62.7 % after buffering with aqueous sodium acetate to pH 5 in 
order to liberate the free base which allowed extraction in warm 2-propanol (Scheme 2.9). 
 
 Scheme 2.9 Synthesis of (5).reagent and conditions: t-BuOH / HCl reflux for 3-4 hrs (62.7 %)  
The S-butyl protection proceeded through a SN1 reaction involving the formation of the t-
butyl cation as the rate determining step of the reaction (Scheme 2. 10).15 
 
Scheme 2. 10.  Proposed mechanism of S-butylation.15 
A key diagnostic signal in the 1H NMR spectrum of (2S)-2-amino-3-(2-(tert-butylthio)-1H-
imidazol-4-yl) propanoic acid (5) was the appearance of a new up field resonance appearing 
as a singlet at δH 1.44 ppm integrating for 9 protons confirming that the sulfur protection had 

















multiplet as observed in (4) (from δH 4.20 to 4.07 ppm) suggests a different environment. A 
slight down field shift of the methylene signal, resonating from two doublet of doublets at δH 
3.28 and δH 3.17 ppm in (4) to two doublet of doublets at δH 3.39 and δH 3.30 ppm in (5) that 
was due to the introduction of t-butyl group that donates electron density into the mercapto 
imidazole ring in the near proximity.  
The optical rotation was [α]20D = +14.1 ° (c = 0.7, H2O)  which was in full agreement with 
that reported by Trampota et al.6 
Finally the EI+ mass spectrum displayed a molecular ion at m/z 243.1 calculated for 
C10H17N3O2S: 243.1 supporting the assigned structure of (5).  
2.4.5. Synthesis and characterisation of (2S)-3-(2-(tert-butylthio)-1H-imidazol-4-yl)-2-
(dimethylamino) propanoic acid (6). 
With the protected thiohistidine in our hand, the N-methylation could be performed. The 
synthesis starts with the preparation of sodium triacetoxyborohydride in situ by reacting 
sodium borohydride with three mol equivalents of glacial acetic acid in ethyl acetate which 
was used as solvent.  
The synthesis of (6) was achieved by reacting 3.8 mol equivalents of formalin (37%) with (5) 
in THF, followed by the addition of a concentrated solution of previously prepared sodium 
triacetoxyborohydride. After allowing the reaction to stir at 10°C for 8 hours, TLC showed 
completion. Compound (6) was isolated after crystallization as the free base in poor yield 
(33.7 %) (Scheme 2.11). 
 
Scheme 2.11 Synthesis of (6), reagent and conditions: Formalin, sodium triacetoxyborohydride  / THF , 6-8 h at 
10°C (33.7 %)  
A key diagnostic signal in the 1 H NMR spectrum was the down field resonance of a singlet at 

















2.4.6. Final stage of L-ergothioneine (8) synthesis. 
The synthesis of ergothioneine (8) was achieved in a two step reaction from the intermediate 
(6). The dimethylated product (6) was allowed to react with 1.5 mol equivalents of 
iodomethane at room temperature for 24 hours. After simple filtration and removal of the 
solvent under high vacuum, the crude quaternary amine (7) was deprotected by refluxing in 
acid (conc HCl) for 21 hours, using 2-mercaptopropionic acid as tert-butyl ion scavenger. 
Ergothioneine (8) was isolated as the chloride salt after work up and crystallization in a 
mixture of EtOH/H2O (10:1) in 27.3% yield over 2 steps (Scheme 2.12). 
 
Scheme 2.12 Synthesis of (8).reagent and conditions: (i) NH4OH, CH3I / MeOH  24 h at rt; (ii) HCl, 2-
mercaptoprionic acid  refluxed for 21h (27.3 % over 2 steps).  
The 1H NMR spectrum displayed the right amount of signals and was in full agreement with 
that reported by Trampota et al.6 
The 13C NMR spectrum of ergothioneine (8) displayed a carbonyl signal at δC 177.0 ppm, 
three aromatics carbons resonated respectively at δC 161. 2 ppm (deshielded for C-2'), 128.9 
ppm (for C-4'), 103.4 ppm (for C-5’) and finally three sets of shielded aliphatic carbons, with 
C-2 resonating at δC 60.6 ppm, the characteristic NMe3 signal at δC 55.6 ppm and the 
methylene carbon (C-3) at 24.9 ppm, all in accordance with data recently reported by 
Erdelmeier et al.16, 17 
In addition, the melting point was recorded as 276-279 °C which was in agreement with that 
reported by Sigma-Aldrich (275-277°C).18 
The optical rotation was [α]20D = +138.21° (c = 1; H2O) which was in agreement with that 
reported by Trampota et al [α]25D = +125°(c = 1; H2O).
6  
The HRMS evaluation (ESI+) (m/z 230.0958 [M+]) corresponding to C9H16N3O2S
+ (m/z 







































Counts vs. Mass-to-Charge (m/ z)
226 227 228 229 230 231 232 233 234 235
 
Figure 2.5 HRMS (ESI+) of L-ergothioneine (8.) 
In this research effort, L-ergothioneine was successfully synthesized with many process 
improvements. A key modification of the method was the use of reverse phase C18 
chromatography, thus significantly reducing the amount of salts allowing the crystallization 
of ergorthioneine. However, several attempts to improve the overall yield (21.4 %) were 
unsuccessful.7 
Recently, Erdelmeier et al16, 17 published a new ergothioneine synthesis, completely different 
from that which was reported in two previous patents, whereby cysteine was used as the 
source of sulfur. The author claimed to have developed a biomimetic, environmentally 
friendly method with fewer reaction steps.  
Synthesis of L-ergothioneine in a one pot synthesis sequence using Erdelmeier’s method was 
also investigated; unfortunately even after several attempts we were not been able to isolate a 
pure (L)-ergothioneine from the reaction mixture, cysteine was rather isolated as it was 
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Chapter 3 Synthesis of ergothioneine biosynthetic enzyme substrates 
 
The ultimate aim of this study is to unravel the biosynthesis of ergothioneine in M. tb and in 
the broader sense to better understand its implication for survival of Mycobacteria. While all 
steps in the pathway are interesting, our focus is on the last step of the biosynthesis, i.e. the 
step catalysed by the PLP-dependent lyase, EgtE. EgtE is involved in the cleavage of the 
intermediate, R/S-(β-amino-β-carboxyethyl) ergothioneine sulfoxide, to L-ergothioneine 
and pyruvate.1 The EgtE enzyme of M. tb is the only enzyme in the pathway that has not yet 
been solubly expressed and none of the pathway enzymes have been thoroughly studied due 
to substrate unavailability. In the absence of expressed and purified EgtE, a classical 
purification of this enzyme is planned, using M. smeg. as the source. However, the latter is 
outside the scope of this effort and only crude cell free lysate was considered for the 
transformation of substrates at this time. In order to perform a classical isolation and 
purification of EgtE for kinetic studies, sufficient quantities of its substrate is required. 
3.1. Synthesis and characterization of EgtE substrate, R/S-(β-amino-β-carboxyethyl) 
ergothioneine sulfoxide. 
3. 1. 1. Retrosynthetic Analysis (Method 1) 
In this approach, the proposed retrosynthesis consider cleavage on the distal side of the 
histidine moiety (left of the sulphur atom) of the substrate as depicted in Scheme 3.1, leading 
to a β-chloro-alanine methyl ster and ergothioneine. Thus, S-alkylation with a protected 
chloromethyl alanine ester, derived from serine, would provide the core structure. The 
resulting thioether can be oxidised under controlled conditions using either mCPBA or H2O2 
depending on the solubility of the substrate. Therefore it is required that ergothioneine be 
synthesized in sufficient quantities and protected appropriately.  
Chlorination of the serine hydroxymethyl side chain would lead to the second major 


















Scheme 3.1 Retrosynthesis of EgtE substrate. 
3. 1. 2. Synthesis of the N-Boc protected-β-chloroalanine methyl ester. 
With L-ergothioneine in our hand, attention was focused on the synthesis of the 
chloromethylserine synthon. Commercially available L-serine (9) was protected as the N-
Boc- L-serine methyl ester (10).2 Although the latter intermediate is commercially available, 
we needed large quantities which were beyond our budget.  The challenge was to synthesize 
the protected N-Boc-β-chloro-L-alanine methyl ester (12) without any racemisation or 
inversion of configuration of the chiral centre. The tert-butyloxy carbonyl (Boc) group was 
considered a suitable amine protecting group because of its facile removal by acid treatment.3 
The synthesis of the ester involved acid catalysed esterification steps as outlined by McKillop 
et al,2 whereby methanolic HCl was produced in situ by reacting acetyl chloride with 
methanol in an ice bath. The serine methyl ester was synthesized on a 5 g scale in quantitative 
yield and high purity. The Boc protection was achieved under standard conditions giving 
access to multigram quantities of the N-Boc-L-serine methyl ester (10) in 72.7% yield 
(Scheme 3.2).  
 
Scheme 3.2 Synthesis of (10) reagent and conditions: (i)  MeOH  / CH3COCl  reflux 2 h; ii)   (Boc)2O, Et3N  /  

















The optical rotation, [α]20D = -25.7 °(c = 5, MeOH), was considered to be sufficient by 
comparison with commercially (Aldrich) available L-enantiomer ([α]20D = -18 °(c = 5, 
MeOH) (Aldrich), and with that which was reported by McKillop et al5 [α]20D = -18.9°(c = 5, 
MeOH).5 Based on optical rotation, it can be claimed that the synthesis was completed 
without significant racemization, if any. 
3. 1. 3. Chlorination of the protected serine methyl ester.  
The chlorination of alcohols is an industrially important transformation in organic synthesis 
having a wide range of applications in fine chemical production.4, 5 Thus, the mildest 
conditions for the conversion of the primary alcohol of protected serine to the chloromethyl 
group was sought. Many methodologies have been published to date and more commonly 
utilize Ph3P-CCl4, PCl5, thionyl chloride, phenylmethyleniminium, benzoxazolium, Vilsmier-
Haack and Viehe salts as chlorinating agents.5 As such, Lidia et al 6 reported a simple and 
efficient chlorination method involving the reaction of TCT and DMF. The mechanism 
involves a SN2 nucleophilic substitution via the formation of a Vilsmeier-Haack intermediate 
(I) (Figure 3.1). The Vilsmeier-Haack complex adds to the hydroxyl group to form a labile 
vinyl ether derivative. Upon substitution with the chloride ion, the corresponding alkylhalide 


















Figure 3.1 Proposed mechanism of chlorination of alcohol using Vilsmeier-Haack type complex as a 
chlorinating agent.6 
With sufficient (7.5 g) N-Boc-L-serine methyl ester (10), chlorination of the hydroxymethyl 
side chain could be attempted.7 The chlorination was accomplished by reacting one molar 
equivalent of N-Boc-L-serine methyl ester (10) with the TCT/DMF complex. TLC indicated 
the formation of N-Boc-β-chloro-L-alanine methyl ester (12) after 4 hours at room 
temperature (Scheme 3.3). 
 
Scheme 3.3 Synthesis of (12) reagent and conditions: TCT  / DMF in CH2Cl2 , 4 h at rt  (30.5 %). 
The compound was isolated in 30.5% yield after flash column chromatography and 
crystallization from a mixture of petroleum ether and ethyl acetate. The N-Boc-β-chloro-L-

















exposure time on the column and therefore was used immediately after chlorination and flash 
chromatography. 
A key diagnostic signal in the 1H NMR spectrum of N-Boc-β-chloro-L-alanine methyl ester 
(12) was the slight upfield shift of the methylene proton signal where the substitution 
occurred (Figure 3.2). Thus, the resonance of methylene proton H-3 shifted from δH 3.90 ppm 
in (10) to 3.84 ppm in (12) due to the substitution of hydroxyl by chloride, which is attributed 
to the shielding effect of an adjacent electronegative atom.  
 
Figure 3.2 Methylene proton (H-3) shift in 1H NMR spectrum of N-Boc-β-chloro-L-alanine methyl ester (12) 
compare to N-Boc-L-serine methyl ester (10) in CDCl3 at 400 MHz.  
The chlorination was further confirmed by respectively medium and strong absorption bands 
in the FTIR Infrared spectrum at 809 and 852 cm-1 for the C-Cl stretch.  
The optical rotation was [α]20D = +32.5° ( c = 0.15; CHCl3), which was in accordance with 
that which was reported by Kenworthy et al 7 ([α]21D = +37.8° ( c = 0.15; CHCl3), suggesting 
that the chlorination was achieved without significant racemisation, if any.   
The melting point obtained was 59-61 °C which was in accordance with that reported by 

















Finally, the EI+ mass spectrum displayed a molecular ion at m/z 235.8 [35M-H]+ calculated for 
C9H15
35ClNO4: 236.1 [
35M-H]+, 238.1 [37M-H]+, The fragment corresponding to the loss of 
Boc has been also detected at m/z 138.0 ([35M+- Boc]; 11 %) and 140.0 ([37M+- Boc]; 2.6 %), 
supporting the assigned structure of N-Boc-β-chloro-L-alanine methyl ester (12). 
3. 1. 4. The synthesis of N-Boc-β-chloro-D-alanine methyl ester (13). 
The N-Boc-β-chloro-D-alanine methyl ester (13) was synthesized as an intermediate toward 
the synthesis of the non-natural diastereoisomeric EgtE substrate analogue, hercynyl-D-
cysteine sulfoxide, which may act as an EgtE enzyme inhibitor. This stems from the fact that 
the amine functional group is essential for the PLP mediated lyase initiation and the D-
enantiomer may not be able to undergo normal lyase activity, but result in inhibition instead. 
The same chlorination procedure as described above was applied to Aldrich commercially 
available N-Boc-D-serine methyl ester.  
The N-Boc-β-chloro-D-alanine methyl ester (13) was isolated in low yield of 14.14 % after 
recrystallization in a mixture of petroleum ether and ethyl acetate (Scheme 3.4). 
 
Scheme 3.4 Synthesis of (13), reagent and conditions: TCT / DMF in CH2Cl2 ,  4 h at rt  (14,14 %). 
The N-Boc-β-chloro-D-alanine methyl ester (13) was fully characterized as a novel product. 
The 1H NMR spectrum as well as 13C NMR were identical to the L-enantiomer analogue (12) 


















Figure 3.3  13C NMR spectrum of N-Boc-β-chloro-D-alanine methyl ester (13) in CDCl3 at 100 MHz. 
The optical rotation measured for the D-enantiomer was [α]20D = -35.7° (c = 1, CHCl3) which 
compared well in sign and magnitude to its L-enantiomer at approximately the same 
concentration. Thus, the reactions did not cause any significant racemisation. 
Finally the EI+ spectrum showed the molecular ion at m/z 236.1 [35M-H] + and 238.1 [37M-




37M-H]+, thus supporting the assigned structure of N-
Boc-β-chloro-D-alanine methyl ester (13).  
The chlorination reaction gave the crude products in good yield as TLC indicated complete 
disappearance of starting material and the formation of a relatively clean product. However, 
after silica gel column chromatography a very poor yield was obtained, suggesting that the N-
Boc-β-chloro-alanine methyl ester (D or L enantiomer) were indeed unstable on SiO2, with N-
Boc-β-chloro-D-alanine methyl ester (13) the more unstable enantiomer (14.1 %). Thus, flash 




















Scheme 3.5 Synthesis of (12) and (13), reagent and conditions: (i) a) MeOH / HCl; b) (Boc)2O, Et3N / THF 6 h 
at rt (72.7 % over 2 steps); (ii) TCT / DMF in CH2Cl2 4 h at rt. 12 (30.5 %), 13 (14.1 %) 
3. 1. 5. The synthesis of R/S-(β-amino-β-carboxyethyl) ergothioneine sulfoxide, the EgtE 
substrate.  
With both retrosynthons in hand the next challenge was to synthesize the EgtE substrate, 
(R/S)-β-amino-β-carboxyethyl)ergothioneine sulfoxide. To this end, unprotected 
ergothioneine (8) was directly S-alkylated under basic conditions with the N-Boc-β-chloro-L-
alanine methyl ester (12), and N-Boc-β-chloro-D-alanine methyl ester (13) respectively to 
give hercynyl N-Boc-L-cysteine methyl ester thioether (19), and hercynyl N-Boc-D-cysteine 
methyl ester thioether (20) (Scheme 3.6).  
 


















The two thioether coupled products (19 and 20) were subjected to S-oxidation using one 
equivalent each of mCPBA to afford the hercynyl N-Boc-L-cysteine methyl ester sulfoxide 
(24), and hercynyl N-Boc-D-cysteine methyl ester sulfoxide (25) (Scheme 3.7).  
Finally, deprotection of the Boc group under acid conditions gave the target compounds 
hercynyl L-cysteine methyl ester sulfoxide (26) and hercynyl D-cysteine methyl ester 
sulfoxide (27) (Scheme 3.7). 
 
Scheme 3.7 Outlined Synthesis of 26-27 reagent and conditions (i) mCPBA, H2O / DCM 1:1, 5 hr at 25°C, 24 
(96.3%), 25 (73.2%) (ii) TFA, DCM / H2O, 26 (70.2%), 27 (73.2%). 
3. 1. 6. Coupling of N-Boc protected β-chloro-L and D-alanine with ergothioneine.  
The coupling was performed by improving the method outlined by Ishikawa et al10 especially 
in terms of the purification technique, reverse phase (C18) was introduced instead of tedious 
biogel chromatography.  
A small-scale coupling reaction was performed using 1 mole equivalent of ergothioneine (8) 
with 1.1 equivalent of N-Boc-β-chloro-L-alanine methyl ester (12) in presence of 

















indicated completion after 5 hours. The hercynyl N-Boc-L-cysteine methyl ester (19) was 
isolated in a moderate yield of 51 % after reverse phase (C18) purification.  
Likewise as described above L-ergothioneine (8) was coupled to N-Boc-β-chloro-D-alanine 
methyl ester (13) and purified by reverse phase (C18) chromatography to yield hercynyl N-
Boc-L-cysteine methyl ester (20) in a low yield of 33.3%.  
The mechanism followed by the reaction is still not well known to date, however Ishikawa et 
al.10 suggested that the reaction may possibly occur via the formation of the cyclic 
ethylenimine-2 carboxylic acid intermediate (I) produced by the dehydrohalogenation of the 
β-chloroalanine (Scheme 3.8), followed by the ring opening induced by nucleophilic attack of 
the sulfur atom of ergothioneine, giving products majors (19 and 20) and minor products (II a 
and II b) depending on the orientation of the ring opening, (in this case only the major 
products, hercynyl N-Boc-L-cysteine methyl ester (19) and hercynyl N-Boc-D-cysteine 
methyl ester (20) were isolated in a moderate yield.  
 

















3. 1. 7. Oxidation of the sulfide intermediate, the (R/S) hercynyl cysteine methyl ester 
sulfide. 
In order to prevent or to minimise racemisation of the sulfoxide, mCPBA was preferably used 
because of its milder nature and potential for controlled sulfoxidation compare to hydrogen 
peroxide.11 Fernandez and Khiari 12 highlighted that mCPBA could provide high 
diastereoselectivity under mild reaction conditions for the synthesis of (Ss)-β-sulfinyl 
thioglycosides (32), and (Rs)-β-sulfinyl thioglycosides (34), which was isolated as a single 
isomer (up to 100 % diastereoselectivity) (Scheme 3.9).12 
 
Scheme 3.9 Diastereoselective  sulfoxidation of (32) and (34) using mCPBA as an oxidating agent. 
The oxidation was performed using 1 mole equivalent of mCPBA in an ice bath to avoid any 
over oxidation to the sulfone (Scheme 3.10) 
 

















The three dimensional lowest steric energy conformations (total energy 34.3722 Kcal/mol) of 
the L-hercynyl N-Boc-L-cysteine methyl ester (19) indicates the potential face selectivity 
toward sulfoxidation, that could lead to the SR diastereoisomer sulfoxide derivative, even the 
proton NMR of hercynyl L-cysteine methyl ester (26) displayed some kind of 
diastereoselectivity (3:1 ratio), although the elucidation of crystal structure is still need to be 
established in the future that will determine the absolute configuration of the chiral sulfoxide 
(Figure 3.4). 
 
Figure 3.4 3D possible conformation of the sulfide (19) indicates potential face selectivity (3D ChemBioDraw 
Ultra 11.0, Total energy 34.3722 Kcal/mol, Dipole/Dipole 3.0912, Steric minimise energy) 
The reaction was completed after 5 hours as monitored by TLC. The products (23) and (24) 
were isolated after reverse phase chromatography (C18) in good yield 96.3 % and 73.2% 


















Scheme 3.11 Outlined Synthesis of 24-25. reagent and conditions (i) mCPBA, H2O / DCM 1:1, 5 hr at 25°C, 
24 (96.3%), 25 (73.2%). 
The 1H NMR spectrum of hercynyl N-Boc-L-cysteine methyl ester sulfoxide (24) displayed 
all the signals. Keys diagnostic signals were one aromatic proton which was slightly shifted 
up field, resonating as a singlet at δH 6.10 ppm, confirming the presence of the imidazole ring, 
two α- amino acid protons resonating as a broad singlet at δH 4.07 ppm and as a multiplet 
from δH 3.67 to 3.72 ppm respectively. The α-amino acid proton H-2'' was shielded due to the 
close proximity of the methyl ester and secondary amine; a singlet resonated at δH 2.98 ppm 
integrating for 9 protons suggesting the presence of three equivalent methyl groups attached 
to a nitrogen atom and  the Boc characteristic signal resonated at δH 1.49 ppm. The 
1H NMR 
spectrum of hercynyl N-Boc-D-cysteine methyl ester sulfoxide (25) was similar to that of 
hercynyl N-Boc-L-cysteine methyl ester sulfoxide (24) as expected.  
The EI+ mass spectrum did not reveal the molecular ion, but showed [M+3H]+ at m/z 450.4 
instead, which is probably due to the nitrogen hydrogen acceptor atoms, thus supporting the 
structure of hercynyl N-Boc-L-cysteine methyl ester sulfoxide (24). 
3. 1. 8. Deprotection of hercynyl N-Boc-L and D-cysteine methyl ester sulfoxide. 
With the hercynyl N-Boc-L-cysteine methyl ester sulfoxide (23) and hercynyl N-Boc-D-
cysteine methyl ester sulfoxide (24) in our hand, the last challenge toward the synthesis of the 
target compounds was deprotection. Boc removal was successfully achieved in a mixture of 
DCM / H2O with 1 ml of TFA. The products hercynyl L-cysteine methyl ester sulfoxide (26) 
and hercynyl D-cysteine methyl ester sulfoxide (27) was isolated in a good yield of 70.2 % 
and 73.2 % respectively after crystallization in a mixture of warm ethanol and distilled water. 

















was recovered on all the amounts, even after several attempts using neutral base, or acid or 
conditions. The stability of amino acid methyl esters to hydrolysis is not new, previously it 
has been reported that the acid or base hydrolysis of its methyl ester is more often ineffective 
and only succeeded after resorting to enzyme mediate hydrolysis.13, 14 De la Rosa et al 
unsuccessfully attempted to hydrolyze the methyl ester group of S-methyl L-N-Cbz-cysteine 
methyl ester sulfoxide. After using several reaction conditions, they were unable to isolate 
any identifiable reaction product.14 
Amongst many authors Bryan et al.15, Yoshiaka et al.16 and Wild et al.13 suggested the use of 
pig liver esterase (PLE), Lipase As Amano (LAS) or Porcine Pancreas Lipase (PPL) to 
enantioselectively cleave the methyl ester. Sang-You et al17 suggested the immobilisation of 
the esterase in order to improve the activity and the recyclability of the enzyme. Holland et al 
52 utilized substilisin calsberg enzyme instead, to hydrolyze enantioselectively the methyl 
ester group of S-methyl N-MOC methionine sulfoxide, the hydrolysis gave the acid and the 
unreacted ester product in moderate yield (41 %). In our case esterase from porcine liver was 
unsuccessful and the starting material was recovered unchanged. 
The evidence of structure of hercynyl L-cysteine methyl ester sulfoxide (26) was furnished by 
spectroscopic techniques. Two dimensionsional NMR, HSBC and COSY (Figure 3.7) were 
utilized for a full structural assignment.  
The 1H NMR spectrum of hercynyl L-cysteine methyl ester sulfoxide (26) displayed the 
correct number of resonances as shown in the Figure 3.5. A key signal in the 1H NMR 
spectrum of hercynyl L-cysteine methyl ester sulfoxide (26) was the disappearance of the Boc 
signal at δH 1.47 ppm, one aromatic proton resonating as a broad singlet at δH 7.38 ppm, 
confirming the presence of an imidazole ring. An upfield signal resonating as a singlet at δH 
3.05 ppm integrating for 9 protons showed clearly the presence of the quaternary amine 
(three equivalent methyl groups), a characteristic methyl ester signal resonating as a singlet at 
δH 3.86 ppm, two α-proton amino acid signals resonating as a doublet of doublets at δH 3.89 
for H-2 and as a multiplet upfield signal resonating at δH 3.45 – 3.40 ppm for H-2'' 
respectively. The diastereotopicity of the methylene protons due to the presence of the 
sulfoxide was clearly revealed as a ratio of 3:1 whereby H-1'' resonated at δH 4.08 ppm for 


















Figure 3.5 1H NMR spectrum of  hercynyl L-cysteine methyl ester (26) in D2O at 400 MHz,  
The 13C NMR spectrum of hercynyl L-cysteine methyl ester sulfoxide (26) displayed four 
carbonyl signals resonating at δC 162.6, 162.9, 163.3, and 163.6 ppm respectively confirming 
the presence of two carboxylic acid moieties and two enantiomers due to the sulfoxide 
chirality. Three aromatic signals resonating respectively at δC 120.9, 118.0, 115.1 ppm 
showing clearly the presence of an imidazole ring, also characteristically an α-amino acid 
carbon at δc 72.2 ppm for C-2 and 43.8 ppm for C-2'' shielded due to the amino group 
(inductively withdrawing lesser than NMe3
+ group) in its close proximity, four sets of 
aliphatic signals resonating at δc 66.0 ppm for methylene C-1'' (major diastereoisomer), 62.9 
ppm for methylene C-1'' (minor diastereoisomer) showing clearly the diastereotopicity 
introduced by the vicinal sulfoxide; a characteristic methyl ester signal at δc 63.8 ppm and 
the trimethylamine signal at δc 43.4 ppm supporting the structure of hercynyl L-cysteine 


















Figure 3.6  13C NMR spectrum of hercynyl L-cysteine methyl ester sulfoxide (26) in D2O at 400 MHz. 
The FTIR spectrum revealed a characteristic strong absorption band at 3409 cm-1 
corresponding to the free amine, which supported Boc deprotection, while a diagnostic strong 
absorption band at 1142 cm-1 (S=O stretch bond) for the sulfoxide, suggested that the sulfur 
oxidation has successfully occurred.18  
The optical rotation of hercynyl L-cysteine methyl ester sulfoxide (26) was [α]20D = -30.26° (c 
= 0.39, H2O). Finally, a correct HRMS evaluation (ESI
+) (m/z 348.1465 [M+H]+) 
corresponding to C13H24N4O5S
+  (m/z 348.1462 [M+H]+) supported the structure of hercynyl 


















Figure 3.7  1H - 1H  COSY  NMR  spectrum of hercynyl L-cysteine methyl ester sulfoxide (26) in D2O at 400 
MHz. 
The unsuccessful methyl ester hydrolysis to afford the EgtE substrate has led us to investigate 
an alternative synthetic route. The methyl ester has been used as a carboxylic protecting 
group, thinking that it could easily be deprotected in the final compound under aqueous basic 
conditions. Unfortunately the methyl ester removal was unsuccessful after trying: a) basic 
conditions using LiOH in THF/MeOH/H2O gradually increasing the temperature from room 
temperature to 50°C, many reactions conditions were investigated including changing solvent 
and bases, but without success; b) acidic conditions using 6 N HCl refluxing for more than 24 
hours and c) a porcine liver esterase enzyme at room temperature in a phosphate buffer (pH 
7-8) was considered, but also without success13 (Scheme 3.12). It has been reported that 


















Scheme 3.12 method 1. LiOH/THF/MeOH/H2O rt to 50°C 24 h;  method 2. 6 N HCl reflux 24 h;  method 3. 
H2O reflux 48 h; method 4. esterase from porcine liver, pH 7-8 at rt 24 h.  
The need for an alternative protecting group has led us to consider the preparation of an allyl 
ester which can be removed under neutral conditions using either Pd(PPh3)3 or Rh(PPh3)3 
mediated homogenous catalysis.  
3. 1. 9. Synthesis of N-Boc-β-chloro-L-alanine allyl ester (14). 
Once again due to budgetary constraints and the need for gram quantities of the N-Boc 
protected β-chloro-L-alanine allyl ester (14), a multigram-scale synthesis of the commercially 
available N-Boc protected L-serine allyl ester (11) was undertaken. The synthesis involved a 
two step reaction in one pot as described by Navickas et al.19  
The cesium carbonate salt of N-Boc-L-serine was prepared, followed by the addition of one 
equivalent of allyl bromide using DMF as a solvent (Scheme 3.13). The N-Boc protected L-
serine allyl ester (11) was isolated in 60 % overall yield after aqueous work up and silica gel 
flash column chromatographic purification. 
 
Scheme 3.13 Synthesis of (11), reagent and conditions: a) Cs2CO3 / MeOH; b) DMF / allylbromide 20 h at rt 
(60 % over 2 steps).  
In the 1H NMR spectrum of the N-Boc protected L-serine allyl ester (11) the downfield 
methylene signal resonated as doublet of quartets at δH 5.22 ppm, the vinyl proton resonated 

















4.46 to 4.34 ppm, characteristic of an allyl ester. All other signals in the proton NMR were in 
full agreement with that which was reported by J. Alsina et al.20 
The same chlorination procedure as described above was applied to N-Boc-L-serine allyester 
(11) synthesized previously. The compound N-Boc-β-chloro-L-alanine allyl ester (14) was 
isolated after flash silica gel column chromatography as yellow oil in very good yield of 
88.5% (Scheme 3.14). 
 
Scheme 3.14 Synthesis of (11), reagent and conditions: TCT / DMF in CH2Cl2  10 h at rt (88.5 %).  
The compound was fully characterized as we couldn’t find any data from the literature for 
direct comparison. The proton NMR as well as 13C NMR displayed the right amount of 
signals but didn’t show much difference with its alcohol (11) as expected, although all 
chemical shifts measured in the same deuterated solvent (CDCl3) were slightly shifted 
compare to its alcohol which implies different compound.  
The evidence of the chlorination was furnished by EI+ mass spectrum, although the molecular 
ion wasn’t shown, the mass corresponding to the loss of Boc, very labile group toward low 
mass spec technique, was shown in a high abundance of 30 % at m/z 160.1 [MCl35-Boc - H]+, 
m/z 162.1 ([MCl37-Boc - H]+, 10 %) and the base peak at m/z 133.0 fragment corresponding 
to the lost of subsequently Boc and an ethyl group characteristic of fragmentation of α-amino 
acid (scheme 3.15), as shown by Schmidt et al 36 in their work on a mass spectrum of 
conjugated amino acid, they proved that most α-amino acids could easily lose the carboxylic 
acid moiety, ethyl group, isopropyl group in their EI positive mass spectrum depending on 
the structure of the amino acid parent. 
In addition TLC revealed a new less polar spot at Rf 0.75 (hexane/EtOAc 2: 1) compared to 
N-Boc-L-alanine allyl ester (11) at Rf 0.25 (hexane/EtOAc 2: 1), as expected, due to the 
substitution of an OH by a less polar chloro group. The FTIR infrared spectrum couldn’t give 
us any useful information as the C-Cl absorption band interfered with the chloroform signal 


















Scheme 3.15 Proposed fragmentation of N-Boc-β-chloro-L-alanine allyl ester (14) observed in the EI+ mass 
spectrum  
3. 1. 10. Deprotection of the allyl compounds. 
The mechanism of allyl deprotection using RhCl(PPh3)3 (Wilkinson’s catalyst) as 
homogenous catalyst is still not well known to date.  
Based on the earlier proposed mechanism by Lim et al 21 and Sato et al,22 the deprotection 
could proceed through catalytic cycle as shown in Figure 3.8. Subsequent RhCl(PPh3)3 (16 
es) activation to the reactive form of the catalyst RhCl(PPh3)2 (14 es), the determinant 
interaction required for the catalytic process could be the coordinative interaction between the 
oxygen of the ally ester with the Rhodium of the catalyst (iii and iv), the last step could be the 
cleavage of the intermediate (iv) to carboxylic acid (v) (major product), volatile alkane (vi) 
and RhCl(PPh3)3 used again in the cycle.  
The catalytic activation could proceed using heat, micro wave or ultra violet light, in our 
project the reaction mixture in EtOH / H2O (80:20) was refluxed at 90 °C, reaction conditions 


















Figure 3.8 Proposed mechanism of allyl deprotection using Rh(PPh3)3Cl as catalyst. 21, 22 
 
3.2 Biomimetic synthesis of EgtE, R/S-(β-amino-β-carboxyethyl) ergothioneine 
sulfoxide. 
3. 2. 1. Retrosynthetic analysis (Method 2) 
In this approach, the proposed retrosynthesis consider a biomimetically inspired cleavage on 
the right hand side of the sulfur atom of the substrate resulting in retrosynthons, 2-bromo 


















Figure 3.10.  Retrosynthesis of EgtE.   
A synthetic method originally inspired by Ito et al.23 in 1985 was recently revised, reporting a 
protecting group-free green synthesis of ergothioneine using fewer steps.24 Intriguingly, the 
reactivity of the histidine imidazole ring was utilized to synthesize ( ne pot) the thioether (28) 
in a moderate yield of 58 % (Scheme 3.16).   
 
Scheme 3.16 Cysteinyl hercynine synthesis.24 
This approach is attractive because it was a biomimetic synthesis and the EgtE substrate 
could also be synthesized from hercynine as precursor.1 The EgtE substrate precursor was 
synthesized in fewer steps compared to the natural pathway.  
The synthesis of hercynine was then embarked upon for multiple reasons. This synthetic 
approach will provide us a short, cheap, protecting group free synthesis in water (green 
chemistry) of the hercynyl cysteine thioether, hercynyl cysteine sulfoxide (EgtE enzyme 
substrate) and L-ergothioneine in fewer steps.  
Hercynine (EgtB enzyme substrate) was the first intermediate toward EgtE enzyme substrate 
synthesis, even though commercially available the need of multi gram quantity which was 
beyond our budget has led us to it synthesis. In order to improve the L-hercynine synthesis 

















3. 2. 2. Synthesis of L-hercynine 
The synthesis of L-hercynine was inspired by method developed by Ishikawa et al. 25 with 
some few modifications such as reductive amination and was performed under milder 
reaction conditions (Scheme 3.17). Methyl ester histidine (1) was preferred as starting 
material to N-benzyl histidine which needed to be deprotected under catalytic hydrogenation 
(Pd/C) conditions. 
 
Scheme 3.17 Synthesis of L-hercynine (17), reagent and conditions: (i) CH2O, NaBH (OAc)3 / CH3OH 24 h at 
rt (83.6 %); (ii) CH3I / THF overnight at rt (37 %); (iii) 6 N HCl reflux 16 -20 h (60 %).  
The synthesis of L-hercynine was initiated with the reductive amination of commercially 
available L-histidine methyl ester dihydrochloride (1) using 3.5 equivalents of formaldehyde 
(37 %) and 2 equivalents of sodium triacetoxyborohydride in THF. The resulting N,N-
dimethyl L-histidine methyl ester (15) was isolated in a good yield (84 %) after aqueous work 
up and purification by silica gel chromatography.  
The 1H NMR spectrum of N,N-dimethyl L-histidine methyl ester (15) revealed the 
appearance of a downfield singlet, resonating at δH 2.39 ppm and integrating for 6 protons, 
thus proving that the N,N-dimethylation was successful. Another key diagnostic signal was 
the α-proton which resonated as a triplet that was shifted slightly up field at δH 3.73 ppm as 
result of the shielding effect of –N(CH3)2 in close proximity and characteristic methyl ester 
signal resonated as a singlet at δH 3.69 ppm. Two aromatic signals resonated as singlet 
respectively at δH 6.90 for H-5', δH 7.85 ppm for H-2' and a NH resonance as a broad singlet 


















Figure 3.9 1H NMR spectrum of N,N-dimethyl L-histidine methyl ester (15) in CDCl3 at 400 MHz  
The 13C NMR spectrum of N,N-dimethyl L-histidine methyl ester (15) revealed the 
characteristic downfield carbon signal resonating at δC 41.6 ppm, assigned to the N,N-
dimethyl group displaying the required number of 13C resonances, thus confirming the carbon 
skeleton of the N,N-dimethyl L-histidine methyl ester (15).  
Quaternarization of N,N-dimethyl L-histidine methyl ester (15) was accomplished using 1.5 
molar equivalents of methyl iodide in methanol at room temperature. TLC indicated the 
formation of the product after 24 hours. The L-hercynine methyl ester (16) was isolated in 
37.2 % yield after crystallization from a mixture of warm methanol and diethyl ether. The 1H 
NMR spectrum of L-hercynine methyl ester (16) revealed a characteristic downfield singlet 
resonating at δH 3.32 ppm and integrating for 9 protons. The signal belonging to the NMe3 in 
the 13C NMR spectrum of L-hercynine methyl ester (16) was overlapped by the DMSO-d6 
resonance from δC 40.6 to 39.4 ppm as indicated in the 
13C APT NMR. Finally the EI+ mass 
spectrum displayed a molecular ion at m/z 213.0 [M+H]+ calculated for C10H19N3O2
+: 212.1 
supporting the assigned structure of L-hercynine methyl ester (16).  
With L-hercynine methyl ester (16) in hand, the final step toward L-hercynine (17) was the 
hydrolysis of the methyl ester. At first attempt, normal basic hydrolysis was applied.  
However, the methyl ester hydrolysis was unsuccessful even though many different reaction 

















may also be influenced by the steric hindrance effect of the bulky -N(CH3)3 group which is 
making the carbonyl inaccessible to any nucleophilic attack.  
Due to the failure of base mediated ester hydrolysis, acid hydrolysis was attempted. 
Successful deprotection of hercynine methyl ester (16) was accomplished by refluxing the 
starting material L-hercynine methyl ester (16) in excess of 6 N HCl to afford L-hercynine 
(17), which was isolated in a moderate yield of 60 %. (Scheme 3.18) 
 
Scheme 3.18 Hydrolysis of L-hercynine methyl ester (16), reagent and conditions: 6 N HCl reflux overnight 
(60 %). 
In the proton NMR spectrum of L-hercynine (17), the absence of a methyl ester signal at δH 
3.67 ppm in (16) indicated successful hydrolysis.  
All 13C NMR resonances were accounted for in the spectrum confirming the carbon skeleton 
of L-hercynine (17).  
In addition the FTIR spectrum revealed a medium absorption band at 1632 cm-1 (C=O 
stretch) for carboxylic acid. The optical rotation was [α]20D = +48.7°(c = 0.9, 5N HCl) which 
was in accordance with that reported by Reinhold et al [α]20D = +44.5°(c = 1, 5N HCl).
25 
Finally the EI+ mass spectrum displayed the sodium adduct of L-hercynine (17) at m/z 223.6 
which requires 223.11 for C9H18N3NaO2
+.  
3. 2. 3. Alternative synthesis of L-hercynine. 
Inspired by the method developed by Fattori et al.26 hercynine was also synthesized in a one 
step reaction using exces of Me2SO4 (2.6 mol equivalents) as methylating agent under basic 
conditions (NaOH 10 %) (Scheme 3.19). The proton NMR displayed a reasonably pure 


















Scheme 3.19 One step Synthesis of L-hercynine (17), reagent and conditions: NaOH (10 %) / Me2SO4 (2.6 
mol equivalents), 30 min at 0° C and 30 min at rt.26 
3.2.4. Synthesis of (R/S)-hercynyl cysteine thioether. 
With the L-hercynine in hand, our next challenge was to couple it to cysteine via the 2-bromo 
hercynine intermediate. This reaction required many attempts in order to improve the yield 
and purity. Only an excess of L-hercynine (3 to 5 equivalents) could afford the desired 
product, thus complicating the purification process. Similar observations were pointed out by 
Erdelmeier et al 27 that very recently published the new synthesis of L-ergothioneine. 
3.2.4.1. Bromination of L-hercynine. 
Bromination (aromatic electrophile substitution) at the C-5 position of the imidazole ring to 
form the reactive intermediate (bromo lactone), reacts with cysteine (nucleophile) to give the 
desired thioether driven by aromatization (Figure 3.10).27  
 

















The author established the position of bromination on the basis of the proton NMR spectrum, 
which revealed only the H-2 resonance.46 
The bromination was performed using a slight excess of bromine (1.3 molar equivalent) 
added drop wise in an ice water bath (0 - 5°C) for preventing the formation of much possible 
by products, noteworthy the labile bromo intermediate was not isolated even after several 
tentatives.23, 27 
In order to prove that bromo lactone is indeed the reactive intermediate, N acetyl L-histidine 
and L-histidine methyl ester derivatives were treated with bromine respectively, followed by 
treatment with cysteine. Only the derivatives with the free carboxylic acid (N-acetyl L-
histidine) led to a reasonable amount of the desired product. Thus, the free carboxylic acid is 
a prerequisite feature for this proposed mechanism.  
3.2.4.2. Synthesis and characterisation of (R/S)-hercynyl cysteine thioether (28). 
L-hercynine (17) was rapidly brominated using Br2 in HCl at 0 °C. Five equivalents of L-
cysteine was added after the formation of an orange yellow solid and the reaction mixture 
was allowed to stir for 1 h at 0 °C. TLC indicated the disappearance of hercynine after 90 
min. The hercynyl cysteine thioether (28) was isolated as a yellow solid (47%) as the 
trihydrochloride hydrate salt after Dowex ion exchange chromatography, followed by reverse 
phase chromatography (C18). 
The proton NMR spectrum of hercynyl L-cysteine thioether (28) displayed two characteristic 
signals for the α-amino acid protons, the first resonating at δH 4.53 ppm as doublet of 
doublets suggesting a coupling with the non-equivalent neighbouring methylene protons. The 
second characteristic signal resonated at δH 4.42 ppm as a triplet, suggesting a coupling with 
methylene protons, slightly deshielded as an effect exerted by the amino group of the 
neighbouring cysteine moiety (lesser electrowidrawing group than NMe3
+). This was 
indicative that the coupling had successfully occurred. The characteristic three N-methyl 
resonances appeared between δH 3.31 and 3.16 ppm as a multiplet integrating for 9 protons. 
Surprisingly, the aromatic proton H-5’ resonated as two signals integrating for one proton at 
δH 8.77 and 7.47 ppm. This is possibly due to the presence of two different tautomeric forms 


















Figure 3.11 1H NMR of hercynyl cysteine thioether (28) in D2O at 400 MHz  
The 13C NMR of hercynyl cysteine thioether (28) displayed the correct number of resonances 
supporting the carbon skeleton of the hercynyl cysteine thiother (28) and were strongly in 

























Table 3.1. NMR Data of (28) in D2O 
 
Positions δH  (J in Hz) 400 MHz, D2O δC (100 MHz, D2O) 
2 4.53 (dd, 7.6, 4.3, 1H) 67.7 
3 
 
4.02 – 3.88 (m, 1H) 
3.55 (dt, 22.3, 7.6, 1H) 
36.6 
5' 8.77 (d, 7.6, 0.5H), 
7.47 (d, 10.5, 0.5 H) 
118.5 
1'' 3.41 (m, 2H) 24.0 
2'' 4.42 (t, 4.4, 1 H) 54.6 
N(CH3)3 3.31 – 3.16 (m, 9H) 52.0 (3 C) 
C-2' - 134.6 
C-4' - 122.8 
COOH Exchange with D2O 170.7 , 170.3 
 
The melting point was 79 °C with decomposition, which agreed with that reported by 
Erdelmeier et al 41 (77 °C with decomposition).  
Finally, a correct HRMS evaluation (ESI+) (m/z 317.1277 [M]+) corresponding to 
C12H21N4O4S
+ (m/z 317.1284 [M]+) supported the structure of the hercynyl cysteine thioether 
(28).  
3.2.4.3. A salt-free synthesis of (R/S)-hercynyl cysteine thioether (28) 
It was difficult to separate the ammonium salts from the product during purification, which 

















Erdelmeier et al 27 utilized electrodialysis (ED) equipment for desalinisation. We did not 
have access to ED equipment and therefore it was useful to develop an alternative way of 
purifying the hercynyl cysteine intermediate.  
A salt free synthesis of hercynyl cysteine thioether (28) was then investigated. The in situ 
protection of the amino group with Boc and the carboxylic groups as the benzyl esters gave a 
sufficiently hydrophobic product, ideal for organic extraction. Thus, after extraction and 
silica chromatography, the salt-free product was obtained. 
The amino and the carboxylic acid groups of the crude hercynyl cysteine thioether (28) were 
protected in a one pot synthesis, affording the fully protected hercynyl L-cysteine thioether 
derivative (29) (Scheme 3.20). 
 
Scheme 3.20. One pot double protection of crude (28), reagent and conditions: a) Boc2O / NaOH, H2O / 
CH3CN, rt overnight b) BnBr / DMF, rt overnight. 37.6 %. 
Two dimensionnal NMR HSQC, COSY and 13C-APT NMR were utilized for full structural 
assignment of hercynyl benzyl ester N-Boc-L-cysteine benzyl ester (29). The key resonance 
in the proton NMR of hercynyl benzyl ester N-Boc-L-cysteine benzyl ester (29) was a 
multiplet resonating from δH 8.63 to 8.24 ppm integrating for 10 protons due to the phenyl 
ester groups as well as the benzylic methylene protons resonating as a singlet at δH 4.72 for 
H-1'', while H-1'''' appeared at δH 4.44 ppm, clearly showing that the benzyl esterification had 
occurred successfully. The Boc signal resonated at δH 2.68 ppm due to the deshielding effect 
of the neighbouring benzyl ester, thus confirming that crude hercynyl cysteine thioether 
(crude 28) was indeed fully protected (table 3.2). 
The 13C NMR of hercynyl benzyl ester N-Boc-L-cysteine benzyl ester (29) displayed the right 




















Table 3.2. Characteristic NMR Data of (29) in DMSO-d6 
 
Positions δH (400 MHz, DMSO-d6) δC (100 MHz, DMSO-d6) 
Boc 2.68 (s, 9H) 36.3 
68.0 (C) 
168.7  (C=O) 
1'' 4.72 (s, 2H) 70.4 
1'''' 4.44 (s, 2H) 69.5 
2 X Phenyl 8.63 – 8.24 (m, 10H) 129.7, 129.1, 128.8, 128.5, 
128.0, 127.8, 127.1, 126.9 
 
Global deprotection of hercynyl benzyl ester N-Boc L-cysteine benzyl ester (29) was 
achieved by hydrogenation (Pd/C) in the presence of TFA under 50 psi pressure (Scheme 
3.21). 
 

















The salt free hercynyl cysteine thioether (28) was fully characterized and the NMR data were 
strongly in agreement with that which was reported in the literature.27 
3.2.5. Oxidation of hercynyl L-cysteine thioether (28) to (R/S)-(β-amino-β-carboxyethyl) 
ergothioneine sulfoxide (30), the EgtE substrate.  
With the hercynyl L-cysteine thioether (28) in hand, our final challenge was to oxidize the 
thioether to the sulfoxide, the EgtE substrate. Despite the apparently simple transformation, 
the process chemistry proved to be very challenging. The oxidation reaction was complicated 
due to factors such aqueous solubility, choice of oxidant, reaction time and technique of 
reaction monitoring. The challenge was to find suitable oxidising conditions that would allow 
the synthesis of the sulfoxide without over oxidation to the sulfone. 
Most reaction conditions previously investigated by Ishikawa et al 10 led to an over oxidation 
to the sulfone. However, literature 10 reports proposed the sulfoxide structure without any 
analytical evidence (Scheme 3.22). Holland et al 28 have utilized chloroperoxidase-hydrogen 
peroxide (CPO-catalyzed sulfoxidation) for the oxidation of sulfur to sulfoxide in a moderate 
to high diastereoisomeric excess, thus suggesting that the diastereoselective sulfoxidation is 
not a straightforward process.  
 
Scheme 3.22.  Hercynyl L-cysteine thioether (28) sulfoxidation.  
One equivalent of hercynyl L-cysteine thioether (28) was treated with slight excess of H2O2 
(30 %) at room temperature for 4 hours. The hercynyl L-cysteine sulfone product (30) was 
isolated as white needles in quantitative yield of 93% after recrystallisation of the crude 
product in a mixture of warm EtOH/ H2O.  
The proton NMR spectrum, as expected, was similar to the hercynyl L-cysteine thioether (28) 

















methylene protons, H-1'' which shifted downfield from δH 3.41 ppm in hercynyl L-cysteine 
thioether (28) to δH 3.80 ppm in hercynyl L-cysteine sulfone (30) due to the deshielding effect 
of the sulfone on its neighbouring protons. 
A key diagnostic resonance in the 13C NMR spectrum of hercynyl L-cysteine sulfone (30) 
was the C-1'' signal, resonating at δC 21.2 ppm in hercynyl L-cysteine thioether (28), shifting 
downfield to δC  49.0 ppm in hercynyl cysteine sulfone (30) due to the deshielding effect of 
the neighbouring sulfone (table 3.3). 
Table 3.3. NMR Data of (30) in D2O 
.  
Positions δH  (J in Hz) 400 MHz, D2O δC (100 MHz,D2O) 
2 4.61 – 4.50 (m, 1H) 74.8 
3 3.92 (m , 2H) 49.3 
4' - 136.0 
5' 8.91 – 8.64 (m, 0.5H), 
7.44 (dd, 27.3, 15.3, 0.5H) 
Due to tautomers 
122.4 
2' - 137.5 
1'' 3.86 (dd, 11.3, 7.4, 1H)  
3.75 (dd, 11.3, 7.4, 1H) 
49.0 
2'' 3.34 (d, 7.4, 1H) 52.5 
N(CH3)3 3.70 – 3.37 (m, 9H) 49.9 (3 C) 


















In addition, the FTIR spectrum revealed a characteristic strong absorption band at 1204 cm-1 
corresponding to the sulfone group, thus supported the over oxidation of the thioether (28) to 
the sulfone (30). 
Finally, the HRMS evaluation (ESI+) (m/z 349.1182 [M]+) corresponding to C12H21N4O6S
+ 
(m/z 349.1192 [M]+) supported the structure of the hercynyl cysteine sulfone (30). 
3. 3. Synthesis of deuterated ergothioneine and hercynine. 
With one of the ergothioneine biosynthetic pathway enzyme substrates in our hand, our next 
challenge was to synthesize deuterated hercynine and ergothioneine. Since these compounds 
are commercially unavailable, their synthesis is of great value to ESH research. 
LCMS was utilized as method to monitor the enzyme mediated conversion of the pathway 
substrates to ergothioneine. To this end, it was decided to synthesize deuterium labelled 
ergothioneine and hercynine as LCMS internal standards for quantitation. The stable 
deuterated isotopes are better internal standard as they display the same retention time and 
chromatographic characteristics compared to the natural isotope equivalent, thus making 
quantitation more accurate.  
In addition, the deuterated hercynine was also used as an ergothioneine pathway enzyme 
substrate to follow the production of deuterated ergothioneine.  
3. 3. 1. Synthesis of ergothioneine-d3 
The synthetic approach was inspired by the modified Trampota 29 method as described in 
chapter 2. Deuterated ergothioneine (9) was synthesized in two sequential reaction steps 
starting with the S-t-butyl protected 2-mercapto-histidine (6), derived from mercapto histidine 
(5). Selective N-methylation with methyl-d3 iodide (for 24 hours), followed by S-t-butyl 
deprotection using 2-mercaptopropionic acid (t-butyl scavenger) in HCl gave product (9) 





















Scheme 2.23 Synthesis of (9).reagent and conditions: (i) Formalin, sodium triacetoxyborohydride  / THF, 6-8 h 
at 10°C (33.7 %), (ii) NH4OH, Cd3I (methyl-d3 iodide) / MeOH  24 h at rt; (iii) HCl, 2-mercaptoprionic acid  
refluxed for 21h (quantitative).  
The proton NMR spectrum of ergothioneine-d3 (9) displayed an aromatic proton at δH 6.95 
ppm, a characteristic α-amino acid proton resonating as a multiplet from δH 4.34 to 4.13 ppm, 
while a multiplet signal from δH 3.73 to 3.43 ppm, integrating for 6 protons instead of 9, 
suggested the presence of a N,N-dimethyl group due to the introduction of the deuterated 
methyl group, and a methylene proton signal at δH 3.41 ppm resonating as a doublet of 
doublets (J = 11.3, 8.5 Hz) for H-3 (Figure 3.12). 
 
Figure 3.12 1HNMR of ergothioneine-d3 (9) in D2O at 400 MHz 
The 13C NMR spectrum of ergothioneine-d3 (9) displayed a carbonyl signal at δC 180.34 ppm, 
three aromatic signals respectively at δC 134.9, 119.1 and 115.8 ppm for the imidazole ring; 
three aliphatic signals at δC 75.5 ppm for the α-carbon amino acid (C-2); a signal at 52.5 ppm 
integrating for two methyl groups due to NMe2; and 22.7 ppm for C-3 confirming the carbon 

















The HRMS evaluation (ESI+) (m/z 233.1161 [M+]) corresponding to C9H13D3N3O2S
+ (m/z 
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Figure 3.13 TIC extracted (top) and ESI HRMS spectrum (bottom) of ergothioneine-d3 (9). 
3. 3. 2. Synthesis of hercynine-d3. 
Deuterated hercynine (18) was synthesized in a two step reaction starting with the 
commercially available L-histidine. The first step involved reductive amination using 
aqueous formaldehyde (37%) and sodium triacetoxyborohydride. The second step involved 
the quaternaryzation of the crude N,N-dimethyl histidine using methyl-d3 iodide under basic 

















61 % after reverse phase chromatography (C18) and recrystallization from a mixture of warm 
EtOH/ H2O. 
The proton NMR spectrum of hercynine-d3 (18) displayed two aromatic signals respectively 
at δC 8.70 ppm for H-2' and 7.45 ppm for H-5', three aliphatic resonances respectively at δH 
4.44 ppm as a doublet (J = 7.7 Hz) for H-2, and two overlapped protons signals resonating as 
a multiplet from δH 3.74 to 3.30 ppm integrating for 8 protons due to NMe2 and H-3. 
The HRMS evaluation (ESI+) (m/z 201.1414 [M+]) corresponding to C9H13D3N3O2
+ (m/z 












































+ESI EIC(201.1414) Scan Frag=175.0V Zac_31Oct_Test_HD_500ng_1.d  
* 27.9
Counts vs. Acquisition Time (sec)
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Chapter 4 Cell free reconstitution of Mycobacterium smegmatis 
ergothioneine biosynthesis 
4.1. Introduction 
It has been demonstrated by Seebeck 1 that in mycobacteria, ESH is synthesized by sequential 
actions of four enzymes named EgtD, EgtB, EgtC and EgtE. Our focus was on the EgtE 
enzyme that catalyses the final step of the ergothioneine pathway, whereby the (SR/S)-
hercynyl cysteine sulfoxide intermediate was transformed to ergothioneine. EgtE of M. tb is 
the only enzyme in the pathway that has not yet been expressed and none of the pathway 
enzymes have been thoroughly studied due to substrate unavailability. The PLP-dependent 
EgtE enzyme could not be purified due to insolubility, which is a common problem with 
cloning and expression of proteins of slow growing organisms in fast growing vectors.9 Thus, 
in the absence of soluble expressed EgtE, a classical purification of this enzyme was planned, 
using M. smeg. as the source. However, the latter is outside the scope of this effort and only 
crude cell free lysate was considered for the transformation of substrates at this time. In order 
to perform a classical isolation and purification of EgtE for kinetic studies, sufficient 
quantities of its substrate is required. The availability of pure EgtE for kinetic studies would 
ultimately allow multiwell plate assays for inhibition studies as required for early M. tb drug 
discovery.  
While the role of ESH is not completely understood, one of the reasons could be due to the 
lack of a rapid, convenient and sensitive direct assay to detect ESH in biological compounds. 
Recent increased interest in ESH as a potential vitamin brought to light several analytical 
methods of detection including LCMS for low level detection.2, 3, 4 
Nguyen et al. 2 developed a rapid HPLC quantification of ESH, based on the reaction of ESH 
with 2,2'–dipyridyl disulphide (2-Py-S-S-2-Py) under acidic conditions, prior to 
chromatographic purification (removing interference of co eluted biological material) 
followed by LCMS (ESI positive mode). The ESH concentration in mushrooms and in animal 
blood were analysed using this method. 
Belo et al. 5 used fluorimetric detection coupled with LCMS (ESI positive mode) of ESH as a 


















per mg protein (equivalent to 573 ± 44 ng of ESH per mg of dry weight). It has been reported 
that cyanobacteria produces a high level of ergothioneine (up to 0.8 106 ng /g dry mass).12  
Having synthesized the ergothioneine biosynthetic precursors, our aim was to prove that the 
compounds are indeed pathway enzyme substrates. Deuterated metabolic intermediates can 
now be utilised as internal standards as well as probes for metabolism. Thus, the metabolic 
transformation was attempted by using fresh, cell free M. smeg lysate, capable of 
enzymatically converting the substrate precursors into ergothioneine.  
4.2. LCMS analysis of the cell free reconstitution of Mycobacterium smegmatis 
ergothioneine biosynthesis assays.   
4.2.1. Extraction of crude enzymes from M. smegmatis.  
Mycobacterium smegmatis is a non pathogenic bacterium, easy to work with and shares 
significant genetic similarities with Mycobacterium tuberculosis. M. smeg. therefore serves as 
a suitable substitute for M. tb to be used as a model organism in our study. 
Mc2155 cultures of Mycobacterium smegmatis were grown and harvested at the exponential 
phase which is characterised by high enzymatic activity as reported by Ashraf et al.6. The 
cells were collected by centrifugation and lysed by sonication. A tablet of complete ultra 
tablets, EDTA-free, glass vials (Roche) containing a cocktail of protease inhibitors was added 
to preserve the enzymatic activities of the crude enzyme preparation after cell lysis.  
In order to reproducibly prepare crude enzyme extracts with the same enzyme concentration, 
the total crude protein level was determined. A protein concentration of 0.17 µg/µl was 




















Figure 4.1 Albumin protein concentration calibration curve. 
4.2.2. LCMS identification of ESH pathway metabolites. 
Ultra high pressure liquid chromatography (UHPLC) was used for analyte separation, 
followed by MS analysis. This method demonstrated sufficient sensitivity and accuracy at 
low analyte concentrations. Due to the polarity and charge on the quaternary ammonium 
group present in all metabolites, poor retention on the UHPLC (Eclipse + C18 RRHD 1.8 
µm.2.1 X 50) column was observed for ESH. Alternative columns were not considered at this 
time as the MS method of detection was sufficiently sensitive and unambiguous.  
The ESI QTOF of the deuterated hercynine metabolites standard was determined prior the 
enzymatic reaction  
4.2.2.1. Deuterated hercynine or [(2S)-N,N,N-2-trimethylamino-d3-3-(1H-imidazol-4-yl) 
propanoic acid] (18) 
The ESI QTOF of the deuterated hercynine metabolites standard (18) was determined prior to 
the crude enzymatic reaction. The ESI QTOF mass spectrum (positive mode) of deuterated 
hercynine (18) displayed a peak at m/z 201.1414 and m/z 202.1454 corresponding to [Md3]
+ 
and [Md3 +H]
+ ions respectively, the accurate mass for deuterated hercynine (18) requires m/z 
201.1431 for C9H13D3N3O2
+[Md3]





























































+ESI EIC(201.1414) Scan Frag=175.0V Zac_31Oct_Test_HD_500ng_1.d  
* 27.9
Counts vs. Acquisition Time (sec)
























Counts vs. Mass-to-Charge (m/z)
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Figure 4.2 (a) TIC/QTOF trace of hercynine deuterated (18) (b) EIC/QTOF of hercynine deuterated (18) (c) 
ESI/QTOF mass spectra of deuterated hercynine (18) in positive ion mode. Data acquired by injection 10 µl 
solution in 3 % acetonitrile, 0.1 % formic acid in milli-Q water. 
4.2.2.2. Hercynyl cysteine methyl ester sulfoxide or (2S)-N,N,N-2-trimethylammonium-
3-[2- ((2S)-2-amino-2-methoxycarbonyl) ethylsulfinyl)- 1H-imidazol-4-yl] propanoic 
acid (26). 
The ESI QTOF of the (SR/S)-hercynyl cysteine methyl ester sulfoxide metabolites standard 
(26) was determined prior the crude enzymatic reaction. The ESI QTOF mass spectrum 
(positive mode) of (SR/S)-hercynyl cysteine methyl ester sulfoxide (26) displayed peaks at m/z 
348.1465 corresponding to [M+H]+ ions, the accurate mass requires m/z: 348.1462 for 
C13H24N4O5S











































+ESI EIC(349.1832) Scan Frag=175.0V Khonde_Nov5_Std_MS.d  
* 180.8
Counts vs. Acquisition Time (sec)
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Figure 4.3 (a) TIC/QTOF trace of (SR/S)-hercynyl cysteine methyl ester sulfoxide (26) (b) EIC/QTOF of 
(SR/S)-hercynyl cysteine methyl ester sulfoxide (26) c) ESI/QTOF mass spectra of (SR/S)-hercynyl cysteine 
methyl ester sulfoxide (26) in positive ion mode. Data acquired by injection 10 µl solution in 3 % acetonitrile, 
0.1 % formic acid in milli-Q water  
4.2.2.3. (R/S)-hercynyl cysteine or [R/S-(β-amino-β-carboxyethyl) ergothioneine sulfide 
(28) and the sulfone (30)] 
The ESI QTOF of (R/S)-hercynyl cysteine or R/S-(β-amino-β-carboxyethyl) ergothioneine 
sulfide (28) and the sulfone (30) metabolites standards were determined prior to the crude 


















The ESI QTOF mass spectrum (positive mode) of (R/S)-hercynyl cysteine thioether (28) 
showed peaks at m/z 317.1277, 318.1270 and 303.1484 corresponding to [M]+, [M+H]+ and 
[M- CH3]
+ ions respectively. 
The accurate mass determination gave a m/z 317.1277 which requires m/z 317.1284 for 
C12H21N4O4S




































+ESI EIC(317.1277) Scan Frag=175.0V Zac_31Oct_Std_SL_500ng_1.d  
* 31.6
Counts vs. Acquisition Time (sec)































+ESI Scan (31.6 sec) Frag=175.0V Zac_31Oct_Std_SL_500ng_1.d  
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Figure 4.4.(a) TIC/QTOF trace of (R/S)-hercynyl cysteine thioether (28) (b) EIC/QTOF of (R/S)-hercynyl 
cysteine thioether (28) (c) ESI/QTOF mass spectra of hercynyl cysteine thioether (28) in positive ion mode. 


















The ESI QTOF mass spectrum (positive mode) of (R/S)-hercynyl cysteine sulfone (30) 
showed peaks at m/z 349.1177, 350.1269 corresponding to [M]+, [M+H]+ ions respectively, 
the accurate mass determination gave a m/z 349.1177 which requires m/z 349.1182 for 
C12H21N4O6S









































+ESI EIC(349.1182) Scan Frag=175.0V Zac_31Oct_Std_SO_500ng_2.d  
* 37.6
Counts vs. Acquisition Time (sec)





























+ESI Scan (37.6 sec) Frag=175.0V Zac_31Oct_Std_SO_500ng_2.d  
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Figure 4.5 (a) TIC/QTOF trace of (R/S)--hercynyl cysteine sulfone (30) (b) EIC/QTOF of (R/S)-hercynyl 
cysteine sulfone (30) (c) ESI/QTOF mass spectra of (R/S)-hercynyl cysteine sulfone (30) in positive ion mode. 


















4.2.2.4. Ergothioneine (8) and deuterated ergothioneine [(2S)-N,N,N-2-trimethylamino-
d3-3-[2-mercapto-1H-imidazol-4-yl) propanoic acid (9)]  
In order to establish a calibration curve for the quantification of ESH, five different 
concentrations (2, 4, 8, 16, 32 ng/ml) of ESH were prepared (figure 4.6). The ESH detection 
was performed in triplicate, giving a limit of detection (LOD) of 0.56 ng/ml for ESH.7, 8  
Since our experiment was quantitative in design, the limit of quantitation (LOQ) was not 
optimised.  
 
Figure 4.6 Calibration curve of ESH. 
The ESI QTOF mass spectrum (positive mode) of ESH (standard) showed peaks at m/z 
230.0958, 231.0980 and 232.0946 corresponding to [M]+, [M+H]+ and [M+2H]+ ions 
respectively, the accurate mass found m/z 230.0958 requires m/z 230.0963 for C9H16N3O2S
+ 
[M]+ (figure 4.7), the similar fragmentation pattern was also observed by Ey et al.9 in their 
experimental MS spectrum of ergothioneine disulfide. The quantitation was performed on the 





























































+ESI EIC(230.0958) Scan Frag=175.0V Zac_30_Test_EG_32ng_2.d  
* 0.512
Counts vs. Acquisition Time (min)
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Figure 4.7 (a) TIC/QTOF trace of ESH standard (8) (b) EIC/QTOF of ESH standard (8) (c) ESI/QTOF mass 
spectra of ESH standard (8) in positive ion mode. Data acquired by injection 10 µl solution in 3 % acetonitrile, 
0.1 % formic acid in milli-Q water. 
The deuterated ergothioneine (9) displayed a similar fragmentation pattern as that observed 
for ESH, the ESI QTOF mass spectrum (positive mode) of deuterated ESH showed peaks at 
m/z 233.1161 and 189. 1261 corresponding to [M-d3]
+ and [M-d3-CO2]
+ ions respectively. 
The accurate mass determination gave a m/z 233.1161 which requires m/z 233.1152 for 
C9H13D3N3O2S
+[Md3]





















































+ESI EIC(233.1161) Scan Frag=175.0V Zac_31Oct_Std_ED2_500ng_1.d  
* 48.0
Counts vs. Acquisition Time (sec)

































Counts vs. Mass-to-Charge (m/z)
140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310
 
Figure 4.8 (a) TIC/QTOF trace of deuterated ergothioneine (9) (b) EIC/QTOF of deuterated ergothioneine (9) 
(c) ESI/QTOF mass spectra of deuterated ergothioneine (9) in positive ion mode. Data acquired by injection 10 
µl solution in 3 % acetonitrile, 0.1 % formic acid in milli-Q water. 
4.3. Crude enzyme mediated biosynthesis of ESH. 
With the crude M. smegmatis enzyme lysate in hand, the enzyme assay was attempted. The 
enzymatic transformation of the substrate to ergothioneine was evaluated by the production 
of ESH as analyzed by LCMS.  
ESH precursor metabolites, deuterated hercynine (18), (R/S)-hercynyl cysteine methyl ester 
sulfoxide (26), R/S-(β-amino-β-carboxyethyl) ergothioneine sulfide (28) and S/R-(β-amino-β-


















37° C, pH = 7.4 for 1 day, and analyzed by LCMS (Eclipse + C18 RRHD 1.8 µm.2.1 X 50 
column, direct injection of 10 µl in 3 % acetonitrile, 0.1 % formic acid in milli-Q water).9 
The identity of ESH was based on its LC retention time (0.5 minute) and its mass analysis 
(Figure 4.7).  
The control reaction containing only the crude M. smegmatis cell free extract was also treated 
under the same conditions as the four metabolites. The concentration of ESH thus obtained 
was 0.58 ng /ml, which was equated to that of endogenous ESH. This concentration was at 
the limit of detection (0.56 ng/ml), thus any increase in the concentration of ESH in the 
experiment was ascribed to biotransformation of the respective substrates by the crude 
endogenous enzymes of the ESH pathway.  
4.3.1. Biosynthesis of ESH using deuterated hercynine (18) as substrate.  
 
Scheme 4.1. Enzymatic synthesis of ESH using deuterated hercynine  (18) as substrate.  
When deuterated hercynine (18) was used as substrate, as expected, no change in natural ESH 
was observed. However, as expected, the LCMS analysis of the mixture revealed the 
production of deuterated ergothioneine (9) eluting at a retention time of 0.5 min. The HRMS 
(ESI+) displayed a peak at m/z 233.1161 corresponding to [M-d3]
+). Peaks values at m/z 
230.0958 [M]+ or at m/z 231.0980 [M+H]+ belonging to the natural ergothioneine were not 
revealed in the chromatogram. This clearly shows that the crude M. smeg. transformed 
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Figure 4.9. LCMS spectrum of ESH in-vitro reconstititued experiment using hercynine deuterated (18) as 
substrate (a) ESI/QTOF mass spectra of natural ESH standard (8) and (b) ESI/QTOF mass spectra of deuterated 
ESH deuterated producedfrom deuterated hercynine in the reaction mixture.   
4.3.2. Biosynthesis of ESH using hercynyl cysteine methyl ester sulfoxide (26) as 
substrate.  
 


















(SR/S)-hercynyl cysteine sulfoxide methyl ester (26) used as substrate gave slight increase in 
the ESH concentration (0.72 ng/ml) (Figure 4.10). Thus, indicating insignificant 
biotransformation to ESH. This result is indicative that (SR/S)-hercynyl cysteine sulfoxide 
methyl ester (26) could be weak substrate, if any. The carboxyl group of the natural substrate 
may be involved in critical enzyme active site binding. However, this finding needs further 












































+ESI EIC(349.1832) Scan Frag=175.0V Khonde_Nov5_MS2A.d  
* 3.000
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Figure 4. 10.  LCMS spectrum of ESH in-vitro reconstititued experiment using (SR/S)-hercynyl cysteine methyl 
ester sulfoxide (26) as substrate. 
4.3.3. Biosynthesis of ESH using R/S-(β-amino-β-carboxyethyl)-ergothioneine sulfide 
(28) and R/S-(β-amino-β-carboxyethyl) ergothioneine sulfone (30) as substrate. 
 
Scheme 4.3. Enzymatic synthesis of ESH using R/S-(β-amino-β-carboxyethyl) ergothioneine sulfide (28) and 


















(R/S)-hercynyl cysteine thioether (28) biosynthetically produced the highest concentration of 
ESH (2.77 ng/ml). The thioether (28) appeared to be a better substrate than the (SR/S)-
hercynyl cysteine methyl ester sulfoxide (26) or the (R/S)-hercynyl cysteine sulfone (30) 
(Figure 4.11). 
When sulfone substrate (30) was evaluated, only an insignificant increase of ESH 
concentration was detected (0.99 ng/ml). The LCMS chromatogram spectrum (Figure 4.12) 
displayed a peak belonging to basal ESH and the substrate respectively, clearly showing that 
no enzymatic reaction occurred. The sulfone is not expected to undergo β-lyase mediated 
cleavage due to its stability. Furthemore the methylene protons adjacent to the sulfone would 
be relatively acidic, and if deprotonated will result in resonance structures that further 
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Figure 4. 12.  LCMS spectrum of ESH in-vitro reconstititued experiment using (SR/S)-hercynyl cysteine sulfone (30) as 
substrate.  
Krupka et al.10 in their research on elucidating the crystal structure of cystalysin (PLP 
dependent enzyme) from treponema denticola, they found guanidinium groups Arg 401 and 
Arg 369 in the active site which makes strong hydrogen bonds with the carboxylate moiety of 
the substrate, suggesting that the free carboxylic acid moiety is required for the C-S lyase 
enzyme activity. The presence of a methyl ester could be the reason why the methyl ester 
sulfoxide (26) gave poor conversion compare to the free carboxylic acid of the hercynyl 
cysteine thioether (28). Due to the unavailability of the hercynyl L-cysteine sulfoxide, we 
could not establish this fact.  
The LCMS spectrum (Figure 4.11) displayed a significant conversion of the (R/S)-hercynyl 






















































+ESI EIC(317.1277) Scan Frag=175.0V Khonde_Nov5_SL2A.d  
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Figure 4. 11.  LCMS spectrum of ESH in-vitro reconstititued experiment using (R/S)-hercynyl cysteine 
thioether (28) as substrate.  
From these experiments two important conclusions have been deducted. Firstly, the free 
carboxylic acid moiety seems to be required for the enzymatic activity. Only the sulfide (28) 
produced a significant 2.77 ng/ml where asproduced 0.99 ng/ml of ESH, thus better 
enzymatic activity was observed compared to the methyl ester sulfoxide substituted 
derivative (26), which exhibited poor ESH conversion (0.72 ng/ml). 
Secondly the sulfone substrate (30) did not lead to ESH, suggesting that the degree of 
oxidation in the sulfur atom of the substrate could be crucial for the activity (Figure 4.13). 
Chemical lysis through a beta-elimination process of the sulfone requires strong basic or 
acidic medium and hence is not possible under the present conditions.  Still further research 
needs to be conducted to successfully express, purify and crystallize EgtE, which would 



















Figure 4.13 In vitro reconstitution of ESH graph (500 µl reactions containing 20 mM Tris HCl pH = 7.4, 20 
mM NaCl, 0.2 Mm FeSO4.7 H2O, 0.5 mM mercaptoethanol, 250 µl of crude M. smeg. enzymes and 50 mM of 
substrates either (1) (SR/S)-hercynyl cysteine thioether (28) (2) (SR/S)-hercynyl cysteine sulfone (30) (3) 


































































Due to the lack of pure ergothioneine enzymes, the biotransformation of four ergothioneine 
enzymes substrates (18, 26, 28, and 30) to ergothioneine was performed using a crude M. 
smeg. enzymatic preparation, and the production of ergothioneine was monitored by LCMS 
technique. The table 4.1 above displayed the average results of the experiment as it was 
performed in triplicate and repeated several times (more than 3 times); despite the 
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Chapter 5 Conclusion 
 
This thesis focussed the synthesis and cell-free reconstitution of ergothioneine biosynthesis 
M. tb enzyme substrates implicated in ergothioneine biosynthetic pathway as published 
recently by Seebeck.1 A yet undiscovered oxidase converts the synthesized substrate, 
hercynyl cysteine sulfide (26) into the EgtE substrate, hercynyl cysteine sulfoxide. Thus, this 
work contributes to the preparation of tools in order to better understand the role of 
ergothioneine in survival of Mycobacteria.  
The focus of the project was in the last step of biosynthetic pathway, whereby EgtE (PLP 
dependent enzyme) catalysed the C-S lyase of hercynyl cysteine sulfoxide to form 
ergothioneine. This step could be crucial for future ergothioneine inhibition studies, which 
could lead to ergothioneine M. tb drug discovery, although the vital protective role of 
ergothioneine in M. tb still needs to be proven. 
PLP is easily the most versatile coenzyme, derived from vitamine B6.
2 PLP enzymes 
catalyzes a wide range of biochemical reactions depending on the substrate specificity and 
these enzymes synthesize, degrade, and interconvert amino acids.2 Breitinger et al 3 
elucidated the crystal structure of cystathionine β-lyase, a PLP-dependent enzyme that 
catalyzes the C-S cleavage of L-cystathione (Scheme 5.1) 
 
Scheme 5.1 Cleavage of cystathione by cystathionine β-lyase.  
Yamada et al 4 elucidated the crystal structure of L-serine dehydratase (EC 4.3.1. 17) from rat 



















Scheme 5.2 Formation of pyruvate catalysed by L-serine dehydratase (EC 4.3.1.17) enzyme.4.  
Elucidation of the crystal structure of PLP-enzymes and modelling remain powerful tools 
toward the understanding of enzyme-substrate interaction, which is required for the 
development of modern-drug discovery programmes.  
Gannon et al 5 found that L-serine dehydratase (EC 4.3.1.17) is specific for the L-cysteine 
only, substituting (L-cysteine) substrate by the D-cysteine enantiomer resulted in a drastic 
drop in the enzyme activity, thus suggesting that the D-cysteine could be an enzyme inhibitor. 
Therefore the synthesis of hercynyl-D-cysteine sulfoxide (non-natural diastereoisomeric EgtE 
substrate analogue) was attempted, hoping that it may act as an EgtE enzyme inhibitor. 
However due to the unsuccessful attempt to hydrolyse the ester, this activity was not 
determined. 
The inhibition of PLP-enzyme has led to the design of drugs against many diseases; 
Difluoromethylornithine (DFMO), an efficient drug against African Human African 
trypanosomiasis (HAT), constitutes a successful example of the development of a PLP 
inhibitor-based drug (Figure 1.9). DFMO inhibits ornithine decarboxylase (ODC), a PLP-
dependent enzyme implicated in the first step of the trypanothione (TSH) biosynthetic 
pathway.6 Based on the success of DFMO fluorinated hercynyl cysteine sulfoxide, and 
fluorinated hercynyl cysteine sulfone EgtE substrate derivatives as well as simple D-
diastereoisomer analogue of the same EgtE substrate could be developed in the future as a 
potential EgtE M. tb enzyme inhibitors (Scheme 5.3). Thus mechanism based designed 



















Scheme 5.3 Potential EgtE enzyme inhibitors  
Seebeck et al. 1 unsuccessfully attempted to isolate the EgtE enzyme, this result was due to a 
solubility problem of PLP enzyme. Using a classical method for the EgtE purification could 
lead to the elucidation of its crystal structure, which is important for the future drug discovery 
program. 
With the lack of pure EgtE M. tb enzyme, crude M. smeg. enzymes was assayed instead to 
enzymatically convert substrates to ergothioneine, LCMS was used to establish the 
production of the product, ergothioneine. It has been found that the ESH assay which utilized 
mass spectrometry (MS), is one of the best quantification techniques, although is not suitable 
for rapid and routine analysis in biological materials, without prior derivatisation the presence 
of ionic ESH adducts (sodiated, potassated, etc) in biological material made the quantification 
of ESH by MS very complex.7  
The results of this thesis have established a platform development toward M. tb ergothioneine 
inhibitory studies required for the future M. tb drug discovery based on the ergothioneine 
biosynthetic pathway.  
This thesis displays in detail the total synthesis of ergothioneine, as well as its enzymatic 
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Chapter 6 Experimental Section 
6.1. General Procedures 
All solvents were dried by appropriate techniques and freshly distilled before use. All 
commercially available reagents were purchased from Sigma-Aldrich and Merck and were 
used without further purification.  
Unless otherwise stated, reactions were performed under an inert atmosphere of nitrogen in 
oven dried glassware and monitored by thin-layer chromatography (TLC) carried out on 
Merck silica gel 60-F254 sheets (0.2 mm layer) pre-coated plates and products visualized 
under UV light at 254 nm or by spraying the plate with an ethanolic solution of ninhydrin 
(2% v/v) followed by heating.  
Column chromatography was effected by using Merck Kieselgel silica gel 60 (0.040-0.063 
mm) and eluted with an appropriate solvent mixtures. All compounds were dried under 
vacuum before yields were determined. 
Nuclear magnetic resonance spectra (1H and 13C) were recorded on a Varian Mercury 300 
MHz (75 MHz for 13C), Varian Unity 400 MHz (101 MHz for 13C) or a Bruker unity 400 
MHz (101 MHz for 13C) and were carried out in CDCl3, DMSO-d6 and D2O as the solvent 
unless otherwise stated. Chemical shifts are given in ppm relative to tetramethylsilane (TMS, 
δ = 0.00 ppm), which is used as internal standard. Assignments were confirmed by COSY, 
APT and HSQC analysis, when required. Coupling constants (J) are reported in Hertz (Hz). 
The spin multiplicities are indicated by the symbol s (singlet), d (doublet), dd (doublet of 
doublets), t (triplet), m (multiplet), q (quartet) and br (broad).  
Optical rotations were obtained using a Perking Elmer 141 polarimeter at 20°C. The 
concentration c refers to g/100ml.  
Melting points were determined using a Reichert-Jung Thermovar hot-plate microscope and 
are uncorrected. Infra Red spectra were recorded on a Perkin-Elmer FT-IR spectrometer (in 
cm-1) from 4000 cm-1 to 450 cm-1.  
Mass spectra were recorded on a JEOL GC MATE ΙΙ magnetic sector mass spectrometer and 
the base peaks are given, University of Cape Town.  
LCMS analyses were carried out with a UHPLC Agilent 1290 Infinity Series (Germany), 
accurate mass spectrometer Agilent 6530 Qradrupole Time Of Flight (QTOF) equipped with 
an Agilent jet stream ionization source (positive ionization mode) (ESI+) and column (Eclipse 

















Enzymatic reactions were allowed to incubate in Nuaire incubator (DH Autoflow CO2 Air –
jarcketed Incubator), and centrifuged in Eppendhorf centrifuge (Model 5810R, Germany), 
Tygerberg Stellenbosch University, Cape Town, South Africa 
6.2. Compounds synthesized. 
(S, Z)-methyl 2, 4, 5-tris (benzamido) pent-4-enoate (2) 1 
 
In a mixture of THF:H2O (10:90, 67 ml) was added histidine methyl ester dihydrochloride 
(5.0 g; 20.6 mmol). This solution was allowed to stir at 10°C followed by the addition of 
sodium bicarbonate (13.7 g; 163mmol) and then benzoyl chloride (13.7 g; 113 mmol), drop 
wise over a period of 30-60 minutes with efficient stirring. The resulting mixture was allowed 
to equilibrate to room temperature and subsequently allowed to stir for an 18-24 hr period. 
Upon settling, the organic layer was separated, washed with brine, dried (anhydrous MgSO4) 
and filtered. The filtrate was evaporated under vacuum. The resultant solid was mixed with 
60 ml of diethyl ether and left overnight at -10 °C. The diethyl ether was decanted, the solid 
residue dissolved in 30 ml of absolute ethanol and mixed with 3.3 ml of triethylamine. The 
resulting solid was dissolved in 60 ml of diethyl ether and allowed to crystallize for an 18-24 
hour period at -10 °C. The resultant crystals were filtered and washed with 8 ml diethyl ether 
and air dried. The tribenzoyl Bamberger intermediate, (S, Z)-methyl 2, 4, 5-tris (benzamido) 
pent-4-enoate was obtained as a white powder (8.0 g; 82 %). Mp:207-210 °C literature 213-
215°C1; νmax (KBr)/cm-1 3316s (NH) 1748s 1202vs (RCOOCH3) 1671s (RCONHR’) 804m 
(Bz), 1H NMR (400 MHz, CDCl3) δ 9.91 (d, J = 8.7 Hz, 1H, NH-7), 8.84 (s, 1H, NH), 8.07 – 
8.02 (m, 2 H, H-3' H-7'), 7.93 – 7.89 (m, 2 H, H-3'' H-7''), 7.82 – 7.78 (m, 2 H, H-3''' H-7'''), 
7.60 – 7.39 (m, 9 H, meta, para rings A, B & C), 7.16 (d, J = 6.8 Hz, 1 H, NH), 6.78 (d, J = 
9.0 Hz, 1H, H-5), 4.94 (q, J = 6.0 Hz, 1 H, H-2), 3.82 (s, 3 H, OCH3-6), 3.02 (dd, J = 14.9, 
5.7 Hz, 1H, H-3a), 2.80 (dd, J = 14.9, 5.7 Hz, 1H., H-3b), 13C NMR (101MHz, CDCl3) δ 

















2''), 132.7 (C-5'), 132.1 (C-4''' C-6'''), 131.9 (C-5''), 131.7 (C-4' C-6'), 129.8 (C-3' C-7'), 128.6 
(C-3''' C-7'''), 128.4 (C-5'''), 128.1 (C-3'' C-7''), 127.7 (C-4'' C-6''), 127.2 (C-2'''), 127.1 (C-
3''C-6''), 115.8 (C-4), 115.0 (C-5), 53.1 (C-6), 45.1 (C-2), 38.3 (C-3). LRMS (EI+) m/z 
calculated for C27H26N3O5 [MH]
+ 471.2 found 471.1 ([MH] +, 11 %). 
 
(S,Z)-Methyl 2,5-bis(benzamido)-4-hydroxypent-4-enoate (3b) 2, 3 
 
Acetyl chloride (19 ml) was added drop wise to methanol (85 ml) with cooling, resulting in a 
concentrated solution of methanolic HCl. 
(S, Z)-methyl 2, 4, 5-tris (benzamido) pent-4-enoate (2) (6.02 g; 12.8 mmol) was added to 
cold methanolic HCl (prepared as described above). A clear solution was achieved within a 5 
hour period. The resultant solution was concentrated on a rotary evaporator to give an oily 
residue which was mixed with diethyl ether (23 ml) and ice-water (76 ml) and the mixture 
was left at 0-5 °C, overnight. The resulting crystals were washed with 5 ml water followed by 
2 ml of diethyl ether and then allowed to air dry. The (S,Z)-methyl 2,5-bis(benzamido)-4-
hydroxypent-4-enoate (3b) was obtained as a white solid (4.50 g; 95.5 %). Mp: 161-164 °C 
(literature 156-158 °C)1; 1H NMR (400 MHz, CDCl3) δ 9.93 (s, 1H, NH), 8.82 (s, 1H, NH), 
8.21 – 7.72 (m, 4H, H-3' H-7' H-3'' H-7''), 7.49-7.44 (m, 6H, H-4' H-5' H-6' H-4'' H-5'' H-6''), 
7.14 (brs, 1H, OH), 6.81 (s, 1H, H-5), 5.10 – 4.80 (m, 1H, H-2), 3.83 (s, 3H, OCH3), 2.95 (m, 
2H, H-3). MS (EI+) m/z calculated for C20H20N2O5 368.1 found 367.8 ([M]
+; 1.3 %), 354.9 
([M- H2O] 
























(2S)-2-amino-3-(2-mercapto-1H-imidazol-4-yl) propanoic acid (4)1 
 
(S,Z)-methyl 2,5-bis(benzamido)-4-hydroxypent-4-enoate (3b) (4.5 g; 12 mmol) was 
dissolved in a mixture of concentrated HCl (31 ml, 32 %) and 26 ml of water. The resulting 
solution was allowed to stir at 90-93°C, for a 15 hr period, where-upon it was allowed to cool 
to 1-5°C. Benzoic acid (crystals) was obtained, which was filtered and washed with cold 
water (8 ml at 5°C) in order to remove the occluded product. The resulting aqueous solution 
was lyophilised to dryness. The crude residue was dissolved in water (12 ml) followed by the 
addition of KSCN (3.34 g, 34.4 mmol) and heating at 80-90°C for 4-5 hr. The solution was 
allowed to cool followed by treatment with sodium acetate (2.82 g). The mixture was kept at 
5 °C overnight, after which the aqueous layer was separated and the pH adjusted with 
amberlyst 15 (H+ form) (pH 5 to 1). The amberlyst 15 (H+ form) was filtered and the filtrate 
lyophilised to dryness to give compound (2S)-2-amino-3-(2-mercapto-1H-imidazol-4-yl) 
propanoic acid (4) as a white powder (2.01 g; 87.8 %). Mp: 206-208°C (with decomposition) 
Literature 204-206°C (with decomposition)4; νmax (KBr)/cm-1 3465s + 1634s + 1129w 
(RNH2 Free) 2073s (N=C-S) 1383m (RCOO
-), 1H NMR (400 MHz, D2O+DCl) δ 6.87 (s, 1H, 
H-5'), 4.31 (t, J = 6.6 Hz, 1H, H-2), 3.28 (dd, J = 16.1, 6.6 Hz, 1H, H-3a), 3.17 (dd, J = 16.1, 
6.6 Hz, 1H, H-3b),  Carboxylic acid and amine protons signals were exchanged with a D2O. 
13C NMR (101 MHz, D2O) δ 170.5 (C-1), 156.6 (C-2’), 123.3 (C-4’), 116.1 (C-5’), 51.9 (C-
2), 25.4 (C-3). LRMS (EI+) m/z calculated for C6H9N3O2S 187.0 found 187.0 ([M]
 +; 92.7 %). 
  
(2S)-2-amino-3-(2-(tert-butylthio)-1H-imidazol-4-yl) propanoic acid (5) 1 
 
In distilled H2O (18 ml) was added (2S)-2-amino-3-(2-mercapto-1H-imidazol-4-yl) propanoic 
acid (4) (2.27 g; 12.1 mmol), followed by the addition of t-butanol (2.34 g; 31.5 mmol) and 
concentrated hydrochloric acid (4 ml, 37 %). The resulting mixture was heated to 85-90°C 
and kept at this temperature for a 3 - 4 hr period. Subsequently, the reaction mixture was 

















solution to 5.0 with aqueous sodium acetate, followed by lyophilisation to dryness, where 
after the amino acid was extracted with warm 2-propanol. The product (5) was obtained as a 
yellow crystal (1.85 g; 62.7 %). [α]20D = +14.1° (c = 0.7, H2O) lit.[α]
25
D = +13° (c = 1, H2O)
1; 
νmax (KBr)/cm-1 3448s + 1561s + 1051w (RNH2 Free) 2237w (N=C-S) 1703m (RCOOH) 
1337m (CH3) 643 (S-R), 
1H NMR (400 MHz, D2O) δ 7.60 (brs, 1H, H-5’), 4.18 (t, J = 3.0 
Hz, 1H, H-2), 3.39 (dd, J = 11.0, 3.0 Hz, 1H, H-3a), 3.30 (dd, J = 11.0, 3.0 Hz, 1H, H-3b), 
1.44 (s, 9H, t-butyl); LRMS (EI+) m/z calculated for C10H17N3O2S 243.1 found 243.1 ([M]
+; 
4.2%), 199.1 ([M–CO2]
+ ; 7.1 %), 142.0 ([M–CO2–C(CH3)3]
+; 4.2%).  
 
(2S)-3-(2-(tert-butylthio)-1H-imidazol-4-yl)-2-(dimethylamino) propanoic acid (6).1 
 
In a solution of THF (19 ml) was dissolved (2S)-2-amino-3-(2-(tert-butylthio)-1H-imidazol-
4-yl) propanoic acid (5) (1.57 g, 6.45 mmol) followed by the addition of formalin (37 %, 2.04 
g, 25.13 mmol) portion wise. The resulting mixture was allowed to equilibrate to room 
temperature and then sodium triacetoxyborohydride (3.76 g, 17.7 mmol) was added while the 
reaction temperature was maintained at 0-5°C. The resulting suspension was allowed to stir at 
10°C for 6-8 hr. The reaction mixture was cooled to -10°C, and acidified with 2 N HCl (pH 
≤1). The resulting solution was lyophilised and the residue was mixed with a 13 ml methanol 
followed by filtration of the undesired inorganic salts. The filtrate was lyophilised to yield the 
dihydrochloride salt. The free amine was liberated by triturating with aqueous sodium acetate 
to pH 5.0 evaporated to dryness, and extraction into 2-propanol, from where it was 
crystallized. The product (6) was obtained as colourless crystals (590 mg; 33.7 %). 1H NMR 
(300 MHz, D2O) δ 6.30 (s, 1H, H-5'), 3.45 (d, J = 10.7 Hz, 1H, H-2), 3.08 (m, 2H, H-3), 3.01 























Ergothioneine (8), (2S)-N,N,N-2-trimethylethanaminium (2-mercapto-1H-imidazol-4-yl) 
propanoic acid chloride salt (8).1 
 
(S)-3-(2-(tert-butylthio)-1H-imidazol-4-yl)-2-(dimethylamino)propanoic acid (6) (590 mg; 
1.71 mmol) was dissolved in MeOH (10 ml) and the pH was adjusted to 8.8-9.0 with 
ammonium hydroxide, followed by the addition of iodomethane (362 mg, 2.57 mmol) and the 
solution was allowed to stir at room temperature for 24 h. The mixture was concentrated 
under vacuum and the resulting white solid (ammonium chloride) was filtered and the cake 
was washed with methanol. The combined filtrates were evaporated to dryness to afford 
crude S-(tert-butyl) ergothioneine (7). In the presence of 2-mercaptopropionic acid (227 ml; 
272 mg; 2.57 mmol), the crude product (7) was dissolved in 10 ml H2O followed by the 
addition of HCl (7.25 ml, 32%). The resulting mixture was refluxed for 21 hours. After 
cooling the reaction mixture was extracted with EtOAc (4 x 25 ml) and then the aqueous 
layer was adjusted to pH 7 with a solution of ammonia (25% v/v) followed by lyophilisation. 
The residue was again extracted with ethyl acetate (4 x 30 ml) followed by partitioning in a 
mixture of distilled water: ethyl acetate 50:50 (v/v). The aqueous layer was retained and the 
organic phase discarded. The aqueous phase was lyophilised to dryness and the solid residue 
was allowed to stir overnight at room temperature in ethanol. The slurry was then filtered to 
afford the crude ergothioneine. L-(-)-ergothioneine (8) was recrystallized from a mixture of 
ethanol / water (10:1) to yield (8) as a white powder (107 mg; 27.3 % over 2 steps). Mp:276-
279 °C literature 275-277°C; [α]20D = +138.21° (c = 1; H2O)
1; Rf silica gel 0.3 
(methanol/water 9:1); 1H NMR (400 MHz, D2O) δ 7.05 (m, 1H, H-5’), 3.76 (dd, J = 11.7, 4.0 
Hz, 1H, H-2), 2.88 (m, 2H, H-3), 2.75 (s, 9H, NMe3); 
13C NMR (101 MHz, D2O)δ 177.0 (C-
1), 161.2 (C-2'), 128.9 (C-4'), 103.4 (C-5'), 60.6 (C-2), 55.6 (NMe3), 24.9 (C-3); νmax 
(KBr)/cm-1 3138s (NH) 1746s (RCOOH), 1995m (N=C-S), 1403s (C=C aromatic ring); 
HRMS (ESI+): m/z 230.0963 [M]+ . Calculated for C9H16N3O2S






















(Deuterated ergothioneine) (9) 
 
(2S)-3-(2-(tert-butylthio)-1H-imidazol-4-yl)-2-(dimethylamino)propanoic acid (6) (110 mg ; 
0.405 mmol) was dissolved in MeOH (3 ml) and the pH was adjusted to 8.8-9.0 with 
ammonium hydroxide, followed by the addition of iodomethane deuterated (70 mg, 0.61 
mmol) and the solution was allowed to stir at room temperature for 24 h. The mixture was 
concentrated under vacuum and the resulting white solid (ammonium chloride) was filtered 
and the cake was washed with methanol. The combined filtrates were evaporated to dryness 
to afford a crude, deuterated S-(tert-butyl) ergothioneine. In the presence of 2-
mercaptopropionic acid (1.70 g; 16.1 mmol), crude deuterated S-(tert-butyl) ergothioneine 
was dissolved in 2 ml H2O followed by the addition of HCl (1 ml, 32%). The resulting 
mixture was refluxed for 21 hours. After cooling the reaction mixture was extracted with 
EtOAc (3 x 15 ml) and then the aqueous layer was adjusted to pH 7 with a solution of 
ammonia (25 % v/v) followed by lyophilisation. The residue was again extracted with ethyl 
acetate (3 x 20 ml) followed by partitioning in a mixture of distilled water: ethyl acetate 
50:50 (v/v). The aqueous layer was retained and the organic phase discarded. The aqueous 
phase was lyophilised to dryness. Purification by reverse chromatography (C18) and 
recrystallization afforded the product (9) as a yellow solid (127 mg; quantitative). Mp:158-
160 °C (dec); 1H NMR (400 MHz, D2O) δ 6.95 (s, 1H, H-5’), 4.34 – 4.13 (m, 1H, H-2), 3.73 
– 3.43 (m, 6H, H-1'' H-2''), 3.41 (dd, J = 11.3, 8.5 Hz, 2H, H-3); 13C NMR (101 MHz, D2O)δ 
180.3 (C-1), 134.9 (C-2'), 119.1 (C-4'), 115.8 (C-5'), 75.5 (C-2), 52.5 (C-1'' C-2''), 22.7 (C-3); 
HRMS (ESI+): m/z 233.1152 [M]+. Calculated for C9H13D3N3O2S
+, found 233.1161 [M]+.  
 
(S)-Methyl 2-(tert-butyloxycarbonylamino)-3-hydroxypropanoate (10) 5, 6, 7, 8 
  
Acetoyl chloride (64.5 ml) was added dropwise to methanol (10 ml) with cooling, resulting in 
a concentrated solution of methanolic HCl. The solution was allowed to stir for 5 min and 

















to reflux. After refluxing for 2 h, the reaction mixture was allowed to cool and the solvent 
removed by evaporation under reduced pressure to give the crude serine methyl ester 
hydrochloride as a colourless crystalline solid which was used without further purification 
(7.20 g; approx 100%). Serine methyl ester hydrochloride (7.20 g, 60.4 mmol) was suspended 
in THF (144 ml) followed by the addition of Et3N (10.1 g; 99.7 mmol). The resulting 
suspension was cooled to 0°C and a solution of (Boc)2 O (10.3 g, 47.2 mmol) in THF (72 ml) 
was added drop wise over 30 min. The mixture was allowed to warm to rt while stirring for 6 
h, thereafter, the reaction temperature was raised to 50°C for further 2 h. The solvent was 
removed in vacuum, and the residue partitioned between Et2O (100 ml) and H2O (100 ml). 
The aqueous phase was extracted with Et2O (4 x 40 ml) and the combined organic phases 
washed with 3 % HCl (80 ml), 5% NaHCO3 (80 ml) and brine (100 ml). Dried over MgSO4 
and the solvent was evaporated to afford (S)-methyl 2-(tert-butyloxycarbonylamino)-3-
hydroxypropanoate (10) as a colorless oil (7.58 g; 34.6 mmol; 72.6 %). νmax (CH2Cl2)/cm-1 
3607w + 1054s + 1340m (Primary alcohol) 3431m (R2NH) 1742s + 1245s (RCOOMe); 
[α]20D = -25.7 ( c = 5, MeOH), L-(-)-isomer literature [α]
20
D = -18 °(c = 5, MeOH) (Sigma 
Aldrich) and [α]20D = -18.9°(c = 5, MeOH)
5; 1H NMR (400 MHz, CDCl3) δ 5.44 (brs, 1H, 
NH), 4.39 (br. s, 1H, H-2), 3.96 (dd, J = 4.0 Hz, 3.9 Hz, 3H, H-3a), 3.90 (dd, J = 3.9 Hz, 4.0 
Hz, 1H, H-3b), 3.78 (s, 3H, OCH3), 2.11 (brs, 1H, OH), 1.45 (s, 9H, Boc). LRMS (EI
+) m/z 
calculated for C9H17NO5 219.1 found 219.9 ([M]
 +; 8.4 %), 119.9 ([M - Boc] +; 30.9 %).  
(S)-allyl 2-(tert-butyloxycarbonylamino)-3-hydroxypropanoate (11) 9, 10 
 
L-(-)-serine (9) (1.5 g; 14 mmol) was dissolved in a mixture of THF and 2M NaOH (20 ml; 
1:1), and then Boc2O (4.75g, 21.8 mmol) was added portionwise. The resulting reaction 
mixture was allowed to stir at room temperature until completion (ca 7h). The reaction 
mixture was diluted with water (100 ml) and extracted with EtOAc (3 x 50 ml). Subsequently 
the aqueous layer was adjusted to pH 3 using HCl (5%) followed by extraction with EtOAc 
(4 x 50 ml). The combined organic layers were dried over MgSO4 and the solvent was 
evaporated under vacuum to afford yellow oil as crude N-Boc-serine, which was used in the 
next step without further purification. 
The crude mixture (2.75 g; assumed to be 13.4 mmol) was dissolved in MeOH (20 ml) 

















to stir at room temperature for 3 hr and then the solvent was removed under vacuum. DMF 
(20ml) was added to the residue, followed by the addition of allylbromide (1.64 g; 13.6 
mmol), the resulting reaction mixture was allowed to stir at room temperature for 20 hr.  The 
cesium salts were filtered through celite and the DMF filtrate was evaporated to dryness, 
whereby EtOAc (50 ml) was added and the organic layer was washed with an aqueous 
solution of 5% citric acid (2 x 25 ml), followed by brine (3 x 25 ml). The ethyl acetate layer 
was dried over MgSO4, filtered, and then evaporated under vacuum. The crude product was 
purified by flash chromatography on silica gel (hexane: EtOAc 3:1 to 1:1) to afford (S)-allyl 
2-(tert-butyloxycarbonylamino)-3-hydroxypropanoate (11) as a light yellow oil (2.10 g; 8.56 
mmol; 60.0 % over 2 steps); 1H NMR (400 MHz, CDCl3) δ 5.91 - 5.76 (m, 1H, H-2') 5.39 
(m, 1H, NHBoc) 5.22 (dq, J = 11.2, 1.5 Hz, 2H, H-3') 4.46 - 4.34 (m, 2H, H-1') 4.07 - 4.14 
(m, 1H, H-2) 3.78 (dd, J = 10.0, 3.2 Hz, 1H, H-3a ) 3.66 (dd, J = 10.0, 3.2 Hz, 1H, H-3b) 
1.45 (s, 9H, Boc).  
 
(S)-Methyl 2-(tert-butoxycarbonylamino)-3-chloropropanoate (12) 9, 11 
 
2, 4, 6-Trichloro-[1, 3, 5] triazine (1.87 g; 10.1 mmol) was added portion wise in DMF (2ml)  
at an internal temperature was maintained at 25 °C. After the formation of a white solid, the 
reaction was monitored (TLC) until complete disappearance of TCT, thereafter CH2Cl2 (25 
ml) was added, followed by the addition of (S)-methyl 2-(tert-butyloxycarbonylamino)-3-
hydroxypropanoate (10) (2.22 g; 10.1 mmol). The resultant mixture was allowed to stir at 
room temperature, monitored (TLC pet-ether: EtOAc, 1:1) until completion (ca 4 h). The 
reaction mixture was diluted with water (20 ml) and washed with saturated aqueous sodium 
carbonate solution (2 × 15 ml) followed by 1 N HCl and brine. The combined organic phases 
were dried (Na2SO4), filtered and concentrated under vacuum. The residue was purified by 
flash column chromatography (petroleum ether: EtOAc 1:1) and was crystallized and 
recrystallized in a mixture of petroleum ether (40-60°C) and ethyl acetate to afford (S)-
methyl 2-(tert-butoxycarbonylamino)-3-chloropropanoate (12) as a white solid (736 mg; 30.5 
%). Mp: 59-61 °C; νmax (KBr) / cm-1 3362s (NH) 2991s + 2943s (C-H, aliphatic) 1739s 1294s 
(RCOOMe) 809s + 852m (C-Cl); [α]20D = +32.5° (c = 0.15; CHCl3); 
1H NMR (300 MHz, 

















(dd, J = 4.6 Hz, 3.4 Hz, 1H, H-3b), 3.80 (s; 3H, OCH3), 1.46 (s, 9H, Boc); LRMS (EI)
+ m/z 
calculated for C9H15Cl
35NO4 236.1 found 235.8 ([
35M-H]+; 5.3 %), 138.0 ([35M+- Boc ]; 11 
%), 140.0 ([37M+- Boc ]; 2.6 %).  
 
(R)-Methyl 2-( tert-butoxycarbonylamino)-3-chloropropanoate (13) 11 
 
2, 4, 6-Trichloro-[1, 3, 5] triazine (1.83 g; 10.0 mmol) was added portionwise in DMF (2ml) 
at an internal temperature of 25 °C. After the formation of a white solid, the reaction was 
monitored (TLC) until complete disappearance of TCT, thereafter CH2Cl2 (25 ml) was added, 
followed by the addition of β-hydroxyl, [(tert-butoxycarbonyl) amino] -α, methyl propionate 
(2.20 g; 10.0 mmol). The resultant mixture was allowed to stir at room temperature, 
monitored (TLC pet-ether: EtOAc, 1:1) until completion (ca 4 h) The reaction mixture was 
diluted with water (20 ml) and washed with saturated aqueous sodium carbonate solution (2 × 
15 ml) followed by 1 N HCl and brine. The combined organic phases were dried (Na2SO4), 
filtered and concentrated under vacuum. The residue was purified by flash column 
chromatography (petroleum ether: EtOAc, 1:1) and was crystallized and recrystallized in a 
mixture of petroleum ether (40-60°C) and ethyl acetate to afford (R)-methyl 2-(tert-
butoxycarbonylamino)-3-chloropropanoate (13) as a white crystal (336 mg; 14.14 %) Mp: 
60-62°C; νmax (KBr)/cm-1 3367s (NH) 2985s (C-H, aliphatic) 1745s + 1245s (RCOOMe) 
849m + 875m (C-Cl); [α]20D = -35.7° (c = 1, CHCl3), D-(-)-isomer, 
1H NMR (400 MHz, 
CDCl3) δ 5.41 (brs, 1H, NH), 4.74 – 4.67 (m, 1H, H-2), 3.97 (dd, J = 8.3, 3.4 Hz, 1H, H-3a), 
3.84 (dd, J = 8.4, 3.3 Hz, 1H, H-3b), 3.80 (s, 3H, OCH3), 1.45 (s, 9H, Boc); 
13C NMR (101 
MHz, CDCl3) δ 169.6 (C-1), 155.0 (C=O (Boc)), 80.5 (C(Boc)), 54.5 (C-2), 52.8 (C-OCH3), 
45.5 (C-3), 28.3 (3C,(Boc)); LRMS (EI)+ m/z calculated for C9H15
35ClNO4 236.1 found 236.1 
([35M-H]+; 3.5 %), 135.9 ([35M+- Boc]; 2.6 %).  
 
(R)-allyl 2-(tert-butoxycarbonylamino)-3-chloropropanoate (14)11, 12  
 
2, 4, 6-Trichloro-[1, 3, 5] triazine (577 mg; 3.13 mmol) was added portion wise in DMF 

















solid, the reaction was monitored (TLC) until complete disappearance of TCT, thereafter 
CH2Cl2 (20 ml) was added, followed by the addition of (S)-allyl 2-(tert-
butyloxycarbonylamino)-3-hydroxypropanoate (11) (768 mg; 3.13 mmol). The resultant 
mixture was allowed to stir at room temperature, monitored (TLC pet-ether: EtOAc, 2:1) 
until completion (ca 10 h) The reaction mixture was diluted with water (20 ml) and washed 
with saturated aqueous sodium carbonate solution (2 × 15 ml) followed by 1 N HCl and 
brine. The combined organic phases were dried (Na2SO4), filtered and concentrated under 
vacuum. The residue was purified by flash column chromatography (petroleum ether: EtOAc 
2:1) to afford (R)-allyl 2-(tert-butoxycarbonylamino)-3-chloropropanoate (14) as a yellow oil 
(729 mg; 2.76 mmol; 88.5 %); [α]20D = +23.94° (c = 0.35, CH2Cl2); Rf 0.75 (hexane/EtOAc 2: 
1); 1H NMR (400 MHz, CDCl3) δ 5.91 – 5.75 (m, 1H, H-2'), 5.37 (brs, 1H, NH), 5.27 – 5.12 
(m, 2H, H-3'), 4.52 - 4.45 (m, 2H, H-1') 4.39 - 4.30 (m, 1H, H-2), 3.96 (dd, J = 8.1, 3.8 Hz, 
1H, H-3a), 3.91 (dd, J = 8.1, 3.8 Hz, 1H, H-3b), 1.45 (s, 9H, Boc); 13C NMR (101 MHz, 
CDCl3)δ 171.3 (C-1), 154.3 (C=O Boc), 114.1 (C-2'), 72.4 (C-3'), 70.1 (C(Boc)), 63.7 (C-2), 
52.7 (C-1'), 30.5 (C-3), 28.4 (3C, (Boc)); LRMS (EI+) m/z calculated for C6H8ClNO2 161.0 
for Cl35 and 162.0 for Cl37 found 160.1 ([M Cl35-Boc - H]+; 30 %), 162.1 ([M Cl37-Boc - H]+, 
10 %); 133.0 ([M Cl35 - Boc – CH2=CH2 - H]
+; 100 %).  
 
(2S)-Methyl 2-(dimethylamino)-3-(1H-imidazol-4-yl) propanoate (15)13, 14, 15 
 
Histidine methyl ester dihydrochloride (1.5 g; 6.2 mmol) was dissolved in a solution of THF 
(20 ml), followed by the addition in one portion of formaldehyde (37.0 %; 650 mg; 21.7 
mmol). The resulting mixture was allowed to equilibrate to room temperature and sodium 
triacetoxyborohydride (2.62 g; 12.4 mmol) was added at an internal temperature was 
maintained at 0-5°C and acetic acid glacial (200 µl) was added as a catalyst. The solution was 
allowed to stir at room temperature for 18-24 h period. The reaction was quenched with 20 
ml of saturated NaHCO3, extracted with EtOAC (5 x 25 ml), and the remaining water layer 
was retained for recycling. The organic layer was separated, washed with brine, dried 
(anhydrous MgSO4) and filtered. The filtrate was evaporated under vacuum. The resultant oil 
was purified by silica gel chromatography (CH2Cl2: MeOH 80:20) to afford (S)-Methyl 2-

















νmax (CH2Cl2) / cm-1 3456w + 1604m (N-H) 1277 (C-N) 1733m + 1255s (RCOOMe); [α]20D = 
+ 0.6° (c = 6.77, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.85 (s, 1H, H-2'), 6.99 (brs, 1H, 
NH), 6.90 (s, 1H, H-5'), 3.69 (s, 3H, OCH3), 3.55 (t, J = 7.5 Hz, 1H, H-2), 3.08 (dd, J = 15.3, 
7.5 Hz, 1H, H-3a), 2.98 (dd, J = 15.3, 7.5 Hz, 1H, H-3b), 2.39 (s, 6H, H-1'' H-2''); 13C NMR 
(101 MHz, CDCl3)δ 171.5 (C-1), 133.9 (C-2’), 131.5 (C-4'), 118.8 (C-5'), 67.0 (C-2), 51.4 
(C-OCH3), 41.6 (C-1'' C-2''), 25.5 (C-3); LRMS (EI
+) m/z calculated for C9H15N3O2 197.1 
found 197.1 ([M] +; 4.3 %) 136.1 ([M-COOCH3]
+; 66.4 %). 
 
(2S)-Methyl N,N,N-2-trimethylethanaminium-3-(1H-imidazol-4-yl) propanoate (16) 13 
 
(S)-Methyl 2-(dimethylamino)-3-(1H-imidazol-4-yl) propanoate (15) (217 mg; 1.10 mmol) 
was dissolved in methanol (20 ml), and the pH was adjusted to 8-9 with a concentrated 
solution of NH4OH (25 %, 40 µl), followed by the addition of methyl iodide (250 mg; 1.76 
mmol). The resultant solution was allowed to stir at room temperature for 24 hours. The 
solvent was evaporated to dryness to afford a crude product (16) which was recrystallized in 
a mixture of warm methanol and diethyl ether to afford (2S)-methyl N,N,N-2-
trimethylethanaminium-3-(1H-imidazol-4-yl) propanoate (16) as a yellow crystal (87 mg; 37 
%); Mp: 223-225 °C (245 °C dec);1H NMR (400 MHz, DMSO) δ 8.98 (s, 1H, H-2’), 8.44 
(brs, 1H, NH), 7.44 (s, 1H, H-5'), 4.89 – 4.81 (m, 1H, H-2), 3.67 (s, 3H, OCH3), 3.32 (s, 9H, 
H-1'' H-2'' H-3''), 3.15 (dd, J = 9.8, 3.4 Hz, 1H, H-3a) 3.05 (dd, J = 9.8, 3.4 Hz, 1H, H-3b); 
13C NMR (101 MHz, DMSO)δ 166.8 (C-1), 135.2 (C-2'), 126.9 (C-5'), 118.3 (C-4'), 72.6 (C-
2), 52.7 (C-OCH3),40.0 (3C, C-1''C-2''C-3''overlapped by DMSO-d6 signal), 23.0 (C-3); 
LRMS (EI+) m/z calculated for C10H19N3O2
+ 213.1 [MH]+ found 213.0 ([MH] +; 1.0 %),  
141.8 ([M-COOCH3-2 CH3]
























(2S)-N,N,N-2-trimethylethanaminium-3-(1H-imidazol-4-yl)propanoic acid (17), L-
hercynine (17)14 
 
(S)-3-(1H-imidazol-4-yl)-1-methoxy-N,N,N-trimethyl-1-oxopropan-2-aminium (16) (653 mg; 
3.08 mmol) was dissolved 6 N HCl (40 ml) and the solution was allowed to reflux overnight. 
Where upon the solution was allowed to cool at room temperature, thereafter the volatile 
components were removed under vacuum. The residue was dissolved in a minimum amount 
of water (20 ml), treated with a charcoal, filtered through celite, washed with water (3 x 10 
ml) and the combined aqueous extracts were lyophilised to dryness. The crude solid was 
recrystallized in a mixture of warm methanol and diethyl ether to yield dihydrochloride salt 
form of L-hercynine (17) as a white solid (489 mg; 60.0 %). Mp: 240-242°C (with 
decomposition) Lit. 237-239 °C (with dec)13; νmax KBr /cm
-1 3435s (N-H) 1632m (RCOOH) 
1496 w (C=C Aromatic) 1335w (C-N); [α]20D = +48.7° (c = 0.9, 5 N HCl); 
1H NMR (400 
MHz, D2O) δ 8.76 (s, 1H, H-2'), 7.51 (d, J = 12.7 Hz, 1H, H-5'), 4.02 – 3.83 (m, 1H, H-2), 
3.49 (s, 9H, H-1''H-2''H-3''), 3.12 (dd, J = 12.7, 4.1 Hz, 1H, H-3a) 3.06 (dd, J = 12.7, 4.1 Hz, 
1H, H-3b)  13C NMR (101 MHz, D2O)δ 166.8 (C-1), 135.5 (C-2'), 134.3 (C-5'), 118.3 (C-4'), 
72.7 (C-2), 53.0 (C-1''C-2''C-3''), 22.3 (C-3); LRMS (EI+) m/z calculated for C9H17N3NaO2
+ 
223.1 found 223.6 ([M+H+Na]+; 20.4%). 
 
Hercynine (17) synthesis (one pot) 16 
L-histidine (293 mg; 1.6 mmol) was dissolved in NaOH (10 %, 4 ml) followed by the 
addition of Me2SO4 (0.4 ml; 532 mg; 4.2 mmol). The reaction was allowed to stir for 30 min 
at 0°C and for further 30 min at room temperature. The solution was neutralized with 0.5 N 
HCl, and lyophilised to dryness. The residue was triturated with Et2O, to yield the L-






















(2S)-N,N,N-2-trimethylamino-d3-3-(1H-imidazol-4-yl)propanoic acid (deuterated 
hercynine) (18) 
 
L-histidine (200 mg; 1.29 mmol) was dissolved in CH3CN (10 ml), followed by the addition 
in one portion of formaldehyde (37 %; 157 mg; 145 µl; 1.93 mmol. The solution was allowed 
to equilibrate to room temperature, thereafter sodium triacetoxyborohydride (615 mg; 2.90 
mmol) and acetic acid glacial (73 µl) were added at an internal temperature was maintained at 
0-5°C. The resulting solution was allowed to stir at room temperature for 18-24 h period. The 
reaction was quenched with 5 ml of HCl 5 % to pH ≤ 1 and then extracted with EtOAC (5 x 
20 ml), the remaining water layer was retained for recycling. The organic layer was 
separated, washed with brine, dried (anhydrous MgSO4) and filtered. The filtrate was 
evaporated under vacuum to obtain crude N,N-dimethyl L-histidine which was used without 
further purification.  
To the crude N,N-dimethyl L-histidine (374; assumed to be 2.023 mmol) dissolved in MeOH 
(5 ml) adjusted to pH 9-10 with a solution of concentrated ammonia (25%), followed by the 
addition of methyl iodate deuterated (489 mg; 3.034 mmol). The solution was allowed to stir 
at room temperature for 24 hours. The solvent was evaporated under high vacuum to dryness. 
Reverse phase chromatography (C18) and recrystallization in mixture of warm EtOH/H2O 
afforded deuterated hercynine (18) as a yellow solid (249 mg; 61.3%); Mp: 142-145 °C (dec); 
1H NMR (400 MHz, D2O) δ 8.70 (s, 1H, H-2'), 7.45 (s, 1H, H-5'), 4.44 (d, J = 7.7 Hz, 1H, H-
2), 3.74 – 3.30 (m, 8H, H-1'' H-2'' & H-3); HRMS (ESI+): m/z 201.1431 [M]+.Calculated for 
C9H13D3N3O2
+ found 201.1414 [M]+.  
 
(2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-(tert-butoxycarbonylamino)-3-
methoxycarbonyl)- ethylthio)-1H-imidazol-4-yl)] propanoic acid (19) 17   
 
N-Boc-β-chloro-L-alanine methyl ester (12) (93 mg; 0.39 mmol) was dissolved in a mixture 

















of the solution to 9-10. The resulting mixture was allowed to stir at room temperature for 30 
min and subsequently followed by the addition of ergothioneine (8) (89 mg; 0.34 mmol). The 
solution was allowed to stir at 30 °C for 5 hours. The solvent was removed under high 
vacuum to dryness and the crude product was purified by reverse chromatography (C18) to 
afford (2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-(tert-butoxycarbonylamino)-3-
methoxycarbonyl)- ethylthio)-1H-imidazol-4-yl)] propanoic acid (19) as a pale yellow solid 
(92 mg; 0.20 mmol; 51%); 1H NMR (400 MHz, D2O) δ 5.95 (s, 1H, H-5'), 4.51 - 4.43 (m, 1H, 
H-2), 4.27 - 4.19 (m, 2H, H-1''), 4.10 (dd, J = 10.0, 4.0 Hz, 1H, H-3a) 4.05 (dd, J = 10.0, 4.0 
Hz, 1H, H-3b), 3.36 - 3.25 (m, 1H, H-2''), 2.49 (s, 3H, OCH3), 1.59 (s, 9H, H-1''' H-2''' H-3'''), 
1.56 (s, 9H, Boc); LRMS m/z calculated for C18H31N4O6S
+ 431.2 found 431.8 ([M+]; 2.5 %). 
 
(2S)-N,N,N-2-trimethylammonium-3-[2-((2S)-2-(tert-butoxycarbonylamino)-3-
methoxycarbonyl)- ethylthio)-1H-imidazol-4-yl)] propanoic acid (20) 17 
 
N-Boc-β-chloro-D-alanine methyl ester (13) (54 mg; 0.23 mmol) was dissolved in a mixture 
of DCM: H2O (50:50; 3 ml) followed by the addition of Et3N (0.3 ml) which adjusted the pH 
of the solution to 9-10. The resulting mixture was allowed to stir at room temperature for 30 
min and subsequently followed by the addition of ergothioneine (8) (61 mg; 0.23 mmol). The 
solution was allowed to stir at 30 °C for 5 hours. The solvent was removed under high 
vacuum to dryness and the crude product was purified by reverse chromatography (C18) to 
afford (2S)-N,N,N-2-trimethylammonium-3-[2-((2S)-2-(tert-butoxycarbonylamino)-3-
methoxycarbonyl)- ethylthio)-1H-imidazol-4-yl)] propanoic acid (20) as a yellow very 
hygroscopic solid (36 mg; 0.08 mmol; 33 %); 1H NMR (400 MHz, D2O) δ 6.22 - 6.28 (m, 
1H, H-5') 3.16 - 3.25 (m, 9H, H-1''' H-2''' H-3''') 1.45 (s, 3H, OCH3) 1.29 (s, 9H, Boc). Other 
signals were overlapped by huge water peak; LRMS (EI+) m/z calculated for C18H31N4O6S
+ 






















allyloxycarbonyl)- ethylthio)-1H-imidazol-4-yl)] propanoic acid (21) 17 
 
N-Boc-β-chloro-L-alanine allyl ester (14) (728 mg; 2.76 mmol) was dissolved in a mixture of 
THF:H2O (66:34; 15 ml) followed by the addition of Et3N (0.5 ml) which adjusted the pH of 
the solution to 9-10. The solution was allowed to stir at room temperature for 30 min and 
subsequently followed by the addition of ergothioneine (8) (729 mg, 2.76 mmol). The 
solution was allowed to stir at 30 °C for 5 hours. The solvent was removed under high 
vacuum to dryness and the crude product was purified by reverse chromatography (C18) to 
afford (2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-(tert-butoxycarbonylamino)-3-
allyloxycarbonyl)- ethylthio)-1H-imidazol-4-yl)] propanoic acid (21) as yellow hygroscopic 
solid (1.12 g; 2.27 mmol; 82.4%). Mp: 195-197 °C; νmax (CH2Cl2)/cm-1) 3350m (NH) 1732s 
+ 1163s + 1046 (RCOOR) 895s (N=C-S); 1H NMR (300 MHz, DMSO) δ 6.88 (brs, 1H, H-
5'), 5.98 – 5.80 (m, 1H, H-2'''), 5.32 (dd, J = 10.3 ,1.5 Hz, 1H, H-3'''a), 5.20 (dd, J = 10.3, 1.5 
Hz, 1H, H-3'''b), 4.95 (m, 1H, H-2''), 4.58 (t, J = 7.8 Hz, 1H, H-2), 4.07 (m, 2H, H-1''), 3.66 
(t, J = 4.8 Hz, 2H, H-1'''), 3.05 (s, 9H, NMe), 2.98 (m, 2H, H-3), 1.38 (s, 9H, Boc); 13C NMR 
(101 MHz, DMSO) δ 171.1 (C-3''), 155.7 (C-1, C=O(Boc)), 132.8 (C-2', C-3'''), 117.7 (C-2''', 
C-4') 111.4 (C-5'), 78.7 (C-2), 65.0 (C(Boc)), 61.6 (C-1'''), 56.8 (C-2''), 45.8 (C-1''), 44.2 
(NMe3), 28.5 (3C(Boc)), 18.9 (C-3).  
 
(2S)-N,N,N-2-trimethylammonium-3-[2-((R)-2-(tert-butoxycarbonylamino)-3-
hydroxycarbonyl)- ethylthio)-1H-imidazol-4-yl)] propanoic acid (22) 18 
 
(2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-(tert-butoxycarbonylamino)-3 
allyloxycarbonyl)-ethylthio)-1H-imidazol-4-yl)] propanoic acid (21) (304 mg; 0.617 mmol) 
was dissolved in a mixture of EtOH: H2O (80:20, 6 ml) followed by the addition of 
RhCl(PPh3)3 (17mg;  0.019 mmol). The solution was allowed to reflux at 90°C for overnight. 

















by reverse chromatography (C18) to afford (2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-
(tert-butoxycarbonylamino)-3-hydroxycarbonyl)-ethylthio)-1H-imidazol-4-yl)]propanoic 
acid (22) as a yellow solid (252 mg; 90.1%). Mp: 267-270°C (277°C dec); νmax (KBr)/cm-1 
3139s (NH) 2939s (C-H) 1744s (COOH) 1401vs (C=C aromatic ring)1168w (RNH) 664w 
(S-R alkyl); 1H NMR (400 MHz, DMSO) δ 7.50 (s, 1H, H-5'), 3.15 (s, 1H, H-2''), 3.04 (s, 9H, 
NMe3), 1.21 (s, Boc). Others signals were overlapped by huge H2O signal 3.35-3.30 (brs, 5H, 
H-1'' H-3-H-2). 13C NMR (101 MHz, DMSO)δ 158.0 (C-3'' C-1), 123.0 (C-2'), 115.5 (C-4', 
C-5’), 74.0 (C-2), 67.8 (C(Boc)), 45.7 (NMe3), 36.6 (C-2''), 28.8 (C-1''), 18.8 (C-3). Boc 
signals were overlapped by DMSO peaks (40.6 - 39.3 ppm); LRMS (EI+) m/z calculated for 
C17H29N4O6S
+ 417.2 found 379.3 ([M- 2H2O – 2H]
 +; 1.8 %); 351.3 ([M- CO]+; 1.4 %) 
 
(2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-(tert-butoxycarbonylamino)-3-
hydroxycarbonyl)- ethylthio)-1H-imidazol-4-yl)] propanoic acid (23) 
 
(2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-(tert-butoxycarbonylamino)-3-
hydroxycarbonyl)-ethylthio)-1H-imidazol-4-yl)] propanoic acid (22) (135 mg; 0.298 mmol) 
was dissolved in a mixture of H2O:DCM (50:50, 4 ml) followed by the addition of TFA (5 
ml) with cooling in a ice bath (0-5°C). The solution was allowed to stir at room temperature 
for 20 hours, the solvent was evaporated under high vacuum to dryness, and the residue was 
treated with Et2O to remove any by product of the reaction. Purification by reverse 
chromatography (C18) afforded (2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-(tert-
butoxycarbonylamino)-3-hydroxycarbonyl)- ethylthio)-1H-imidazol-4-yl)] propanoic acid 
(23) as pale yellow hygroscopic solid (100 mg; 0.283 mmol; 95.2 %); Mp:162-165°C; νmax 
(KBr)/cm-1 3409 br.m (RNH2, amine) 3142 br.m (OH) 3024 (C-H, aromatic ring) 1675vs 
(C=O) 598w (R-S, sulfur); 1H NMR (400 MHz, D2O) δ 7.62 (s, 1H, H-5'), 4.11 – 4.01 (m, 
1H, H-2), 3.91 (t, J = 9.6 Hz, 1H, H-2''), 3.30-3.20 (s, 9H, NMe3), 3.15 (dd, J = 9.6, 4.1 Hz, 
1H, H-3a), 2.90 (dd, J = 9.6, 4.1 Hz, 1H, H-3b), 2.82 (m, 2H, H-1''); LRMS (EI+) m/z 
calculated for C12H21N4NaO4S






















methoxycarbonyl)- ethylsulfinyl)-1H-imidazol-4-yl)] propanoic acid (24) 
 
(2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-(tert-butoxycarbonylamino)-3 
methoxycarbonyl)-ethylthio)-1H-imidazol-4-yl)] propanoic acid (19) was dissolved in a 
mixture of H2O: DCM (50:50; 4 ml) followed by the addition of mCPBA (13 mg; 0.06 mmol; 
77 %). The solution was allowed to stir at 0-5°C for 3-5 hours until completion (TLC). The 
solution was partitioned in a separator funnel, water layer was returned and organic layer 
discarded. Water layer was treated with amberlyst (H+ form) to neutral and then extracted 
with DCM to remove any organic impurities. Water layer was returned and lyophilised to 
dryness. The residue was purified by reverse phase chromatography (C18) to afford (2S)-
N,N,N-2-trimethylammonium-3-[2-((2R)-2-(tert-butoxycarbonylamino)-3-methoxycarbonyl)- 
ethylsulfinyl)-1H-imidazol-4-yl)] propanoic acid (24) as a pale  yellow crystal (25 mg; 0.06 
mmol; 96 %). 1H NMR (400 MHz, D2O) δ 6.10 (s, 1H, H-5’) 4.07 (brs., 1H, H-2) 3.89 (m, 
2H, H-3) 3.77 (s, 3H, OCH3) 3.72 -3.67 (m, 1H, H-2'') 3.60 (dd, J = 11.72, 6.41 Hz, 1H, H-
1''a) 3.42 (dd, J = 11.72, 6.41 Hz, 1H, H-1''b) 2.98 (s, 9H, NMe3) 1.47 (s, 9H, Boc); MS (EI
+) 
m/z calculated C18H31N4O7S
+ 447.2 found 450.4 ([M + 3H]+, 1.5 %) 
 
(2S)-N,N,N-2-trimethylammonium-3-[2-((2S)-2-(tert-butoxycarbonylamino)-3-
methoxycarbonyl)- ethylsulfinyl)-1H-imidazol-4-yl)] propanoic acid (25) 19 
 
(2S)-N,N,N-2-trimethylammonium-3-[2-((2S)-2-(tert-butoxycarbonylamino)-3-
methoxycarbonyl)-ethylthio)-1H-imidazol-4-yl)] propanoic acid (20) (20 mg; 0.046 mmol) 
was dissolved in a mixture of H2O: DCM (50:50; 4 ml) followed by the addition of mCPBA 
(10 mg; 0.05 mmol; 77 %). The resulting solution was allowed to stir at 0-5°C for 5 hours, as 
indicated by TLC (completion). The solution was partitioned in a separator funnel, the water 
layer was returned and organic layer discarded. Water layer was treated with amberlyst (H+ 

















was returned and lyophilised to dryness, the residue was purified by reverse phase 
chromatography (C18) to afford compound (2S)-N,N,N-2-trimethylammonium-3-[2-((2S)-2-
(tert-butoxycarbonylamino)-3-methoxycarbonyl)-ethylsulfinyl)-1H-imidazol-4-yl)] 
propanoic acid (25) as a white crystal (15 mg; 0.026 mmol; 73%); 1H NMR (400 MHz, D2O) 
δ 6.47 (s, 1H, H-5'), 4.10 – 4.05 (m, 2H, H-1''), 3.92 (s, 3H, OCH3), 3.88 – 3.84 (m, 1H, H-
2''), 3.75 (dd, J  = 11.7, 3.7 Hz, 1H, H-3a), 3.67 (dd, J = 11.7, 3.7 Hz, 1H, H-3b), 3.45 – 3.41 
(m, 1H, H-2), 3.06 (s, 9H, NMe3), 1.46 (s, 9H, Boc). 
(2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-amino-2-methoxycarbonyl) 
ethylsulfinyl)- 1H-imidazol-4-yl] propanoic acid (26). 
 
(2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-(tert-butoxycarbonylamino)-3-
methoxycarbonyl)-ethylsulfinyl)-1H-imidazol-4-yl)] propanoic acid (24) (45 mg, 0.10 mmol) 
was dissolved in distilled H2O (1 ml) followed by the addition of trifluoroacetic acid (1 ml) 
with cooling in a ice bath. The solution was allowed to stir at 0-5°C until completion 
(monitored by TLC). The solvent was concentrated by lyophilisation and the residue was 
extracted with DCM to remove any by product and lyophilised to dryness. The crude product 
was crystallized in ethanol to afford (2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-amino-
2-methoxycarbonyl)ethylsulfinyl)-1H-imidazol-4-yl] propanoic acid (26) as a pale yellow 
and hygroscopic crystal (25 mg; 0.07 mmol; 70%). Mp:108-110°C; νmax (KBr)/cm-1 3409s 
(RNH2) 2086m (N=C-S) 1688vs (COOH) 1434s (C=C aromatic ring) 1206s (C-N) 1142s 
(S=O); [α]20D = -30.26° (c = 0.39, H2O); 
1H NMR (400 MHz, D2O) δ 7.38 (brs, 1H, H-5'), 
4.08 (dd, J = 9.9, 4.7 Hz, 2H, H-1'' major diastereoisomer), 4.02 (dd, J = 9.6, 4.6 Hz, 2H, H-
1'', minor diastereoisomer), 3.89 (d, J = 4.2 Hz, 1H, H-2), 3.86 (s, 3H, OCH3), 3.77 (dd, J = 
11.5, 4.2 Hz, 1H, H-3a ), 3.67 (dd, J = 11.05, 4.2 Hz, 1H, H-3b), 3.45 – 3.40 (m, 1H, H-2''), 
3.05 (s, 9H, NMe3); 
13C NMR (101 MHz, D2O) δ 162.6 (C=O), 162.9 (C=O), 163.3 (C=O), 
163.6 (C=O), 120.9 (C-2'), 118.0 (C-4'), 115.1 (C-5'), 72.2 (C-2), 66.0 (C-1'' major 
diastereoisomer), 62.9 (C-1'' minor diastereoisomer), 63.8 (OCH3), 43.8 (C-2''), 43.4 (NMe3), 




















ethylsulfinyl)-1H-imidazol-4-yl] propanoic acid (27). 
 
Same procedure for the synthesis of compound (26) was followed as described above. (2S)-
N,N,N-2-trimethylammonium-3-[2-((2S)-2-amino-2-methoxycarbonyl)ethylsulfinyl)-1H-
imidazol-4-yl] propanoic acid (27) was isolated as brownish and hygroscopic solid (15 mg; 
73.2 %).            
 
(2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-amino-2-hydroxycarbonyl)ethylthio)- 
1H-imidazol-4-yl] propanoic acid trihydrochloride salt (28) 20, 21 
 
L-hercynine (17) (100 mg, 0.50 mmol) was dissolved in distilled H2O (5 ml), followed by the 
addition of concentrated HCl (37 %, 28 mg, 74 µl, 0.76 mmol). The solution was allowed to 
cool in an ice bath, thereafter Br2 (104 mg, 0.65 mmol) was added drop wise, followed by the 
addition of cysteine monohydrate chloride (439 mg, 2.50 mmol) 5 min later. The reaction 
mixture was allowed to stir for 90 min at 0°C. Purification by Dowex chromatography 
(gradient 0.5-2N HCl, Dowex (50WX8-100) and reverse phase chromatography (C18) 
afforded (2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-amino-2-hydroxycarbonyl) 
ethylthio)-1H-imidazol-4-yl] propanoic acid trihydrochloride salt (28) as a pale yellow 
hygroscopic solid, in trihydrochloride hydrate salt form (193 mg, 46.6 %). Mp: 79°C (dec), 
Lit. 77° C (dec)20; 1H NMR (400 MHz, D2O) δ 8.77 (d, J = 7.6 Hz, 0.5H, H-5'), 7.47 (d, J = 
10.5 Hz, 0.5H, H-5'), 4.53 (dd, J = 7.6, 4.3 Hz, 1H, H-2), 4.42 (t, J = 4.3 Hz, 1H, H-2''), 4.02 
– 3.88 (m, 1H, H-3a), 3.55 (dt, J = 18.2, 7.6 Hz, 1H, H-3b), 3.41 (m, 2H, H-1''), 3.31 – 3.16 
(m, 9H, NMe3);
 13C NMR (101 MHz, D2O) δ 170.8 (C-3''), 170.3 (C-1), 134.6 (C-2'), 122.5 
(C-4'), 118.5 (C-5'), 67.7 (C-2), 54.6 (C-2''), 52.0 (NMe3), 36.7 (C-3), 24.0 (C-1''); HRMS 
(ESI+): m/z 317.1284 [M]+. Calculated for C12H21N4O4S



















butoxycarbonyl)ethylthio)-1H-imidazol-4-yl] benzyl propanoate (29).22 
 
(2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-amino-2-hydroxycarbonyl)ethylthio)-1H-
imidazol-4-yl] propanoic acid trihydrochloride salt (28) (765 mg, 2.51 mmol) was dissolved 
in a mixture of distilled H2O:CH3CN (1:1, 10 ml), followed by the addition portion wise of 
NaOH (100 mg, 2.51 mmol). Tert-butyl dicarbonate (602 mg, 2.76 mmol) was added and the 
solution was allowed to stir overnight at room temperature. The solvent was evaporated under 
high vacuum to dryness, and the residue was triturated with Et2O, dried under vacuum. The 
crude solid was dissolved in DMF (5ml) followed by the addition of benzyl bromide (943 
mg, 5.52 mmol). The solution was allowed to stir overnight at room temperature. The solvent 
was removed under high vacuum to dryness. Purification by chromatography using silica gel 
column (CH2Cl2:MeOH, 70:30) afforded (2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-(tert-
butoxycarbonylamino)-3-butoxycarbonyl)ethylthio)-1H-imidazol-4-yl]benzylpropanoate (29) 
as a brown gum (563 mg, 37.6 %). [α]20D = +0.084° (c = 6.67, MeOH), 
1H NMR (400 MHz, 
DMSO) δ 8.63 – 8.24 (m, 10H, 2Ph), 7.90 (s, 1H, H-5'), 4.72 (s, 2H, H-1''), 5.32 (brs, 2H, 
NH), 4.44 (s, 2H, H-1''''), 3.73 (d, J = 3.1 Hz, 1H, H-2), 3.66 (dd, J = 4.1, 2.7 Hz, 1H, H-2'''), 
3.30 (dd, J = 11.1, 3.1 Hz, 1H, H-3a), 3.25 (dd, J = 16.8, 4.1 Hz, 1H, H-1'''a) 3.18 (dd, J = 
16.8, 4.1 Hz, 1H, H-1'''b), 3.15 (dd, J = 11.1, 3.1 Hz, 1H, H-3b), 2.84 (s, 9H, NMe3), 2.68 (s, 
9H, Boc); 13C NMR (101 MHz, DMSO) δ 169.4 (C=O), 169.2 (C=O), 168.7 (C=O), 138.3 
(C-2'), 136.4 (C-4'), 129.7, 129.1, 128.8, 128.5, 128.0, 127.8, 127.1, 126.9 (8C, 2Ph), 125.57 
(C-5'), 70.4 (C-1''), 69.5 (C-1''''), 68.0 (C(Boc)), 53.7 (C-2), 51.7 (NMe3), 51.3 (C-2'''), 37.7 
(C-3), 36.3 (3C(Boc)), 25.4 (C-1'''); LRMS (EI+) m/z calculated for C25H31N4O4S
+ 483.2 [M- 
Boc- CH3]
+ found 483.7 ([M- Boc- CH3]






















ethylsulfonyl)- 1H-imidazol-4-yl] propanoic acid (30) 
 
(2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-amino-2-hydroxycarbonyl)ethylthio)-1H-
imidazol-4-yl] propanoic acid trihydrochloride salt (28) (924 mg, 2.04 mmol) was dissolved 
in distilled H2O (1ml) followed by the addition of H2O2 (30 %, 231mg, 2.04 mmol). The 
reaction mixture was allowed to stir at room temperature for 4 hours. The solution was 
lyophilized to dryness, the residue was recrystallized in a mixture of EtOH/H2O to afford the  
(2S)-N,N,N-2-trimethylammonium-3-[2-((2R)-2-amino-2-hydroxycarbonyl)ethylsulfonyl)- 
1H-imidazol-4-yl] propanoic acid (30) as white hygroscopic needles (889 mg, 93%). Mp: 62-
64°C; νmax (KBr)/cm-1 3517s (RNH2) 1737vs 1632vs (COOH) 1441s (C=C aromatic ring) 
1204s (SO2); 
1H NMR (400 MHz, D2O) δ 8.91 – 8.64 (m, 0.5H, H-5'), 7.44 (dd, J = 27.3, 
10.8 Hz, 0.5H, H-5'), 4.61 – 4.50 (m, 1H, H-2), 3.92 (m, 2H, H-3), 3.86 (dd, J = 11.3, 7.4 Hz, 
1H, H-1''a) 3.75 (dd, J = 11.3, 7.4 Hz, 1H, H-1''b), 3.70 – 3.37 (m, 9H, NMe3), 3.34 (d, J = 
7.4 Hz, 1H, H-2''); 13C NMR (101 MHz, D2O) δ 172.3 (C=O), 169.8 (C=O), 137.5 (C-2'), 
136.0 (C-4'), 122.4 (C-5'), 74.8 (C-2), 52.5 (C-2''), 49.9 (NMe3), 49.3 (C-3), 49.0 (C-1''); 
HRMS (ESI+): m/z 349.1177 [M]+. Calculated for C12H21N4O6S
+, found 349.1192 [M]+. 
6.3. Total Protein extraction and purification from Mycobacterium smegmatis. 
6.3.1. Mc2155 (M. smegmatis) growth conditions. 
M. smeg culture (800 ml) were grown to exponential phase, and then dried to obtain 10 g of 
dry cells. The obtained pellets of M. smeg cells were thereafter stored at -80°C until it was 
required. 
6.3.2. Total protein extraction. 
M.smeg cells was sonicated for 35minutes at 4°C (25 pulsars), followed by the addition of 
potassium phosphate buffer (60 ml; pH 7). The solution was allowed to stir at 4°C for 10 
minutes and thereafter centrifuged at 3000 rpm for 20 min. The supernatant was collected, 
measured and then the appropriate amount of ammonium sulphate gradually added while 

















After precipitation of total protein the suspension was centrifuged at 4°C at 3000 rpm for 20 
min and stored at -20°C. 
6.3.3. Preparation of buffers. 
6.3.3.1. Preparation of potassium phosphate buffer.  
In distilled H2O (1000 ml) was dissolved NaOH (2g; 50 mmol) to obtain solution A (NaOH 
50 mM; 1000 ml). In distilled H2O (1000 ml) was dissolved KH2PO4 (6.8 g; 50 mmol) to 
obtain solution B (KH2PO4 50 mM; 1000 ml). To solution A (291 ml) of was added of 
solution B (500 ml) and mixed thoroughly to obtain a solution C (potassium phosphate buffer 
50 mM; pH approx 7) 
6.3.3.2. Preparation of a dialysis Buffer. 
To a solution C (791 ml; Potassium buffer 50 mM) was added a solution of pyridoxal 5’-
phosphate (150 ml; 20 µM) and EDTA (50 ml) to obtain the dialysis buffer (1000 ml; pH 
approx 7) 
6.3.4. Total protein purification. 
The complex total protein ammonium salts precipitate was resuspended in dialysis buffer 
mixture (20 ml; pH 7) containing pyridoxal phosphate (10 ml; 20µM), potassium phosphate 
buffer (8 ml; 50 mM; pH 7) and (2 ml; 1mM EDTA). Thereafter the suspension was dialyzed 
against the same buffer until complete removal of ammonium sulphate as confirmed by a 
barium chloride test.23, 24 
6.3.5. Total protein concentration. 
6.3.5.1. Protein calibration curve 
The Protein Dc Assay was used to obtain protein concentrations 
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 Mix together 1ml Reagent A and 20µl Reagent S for every 4 samples and label it 
“Reagent A”. 
 Dilute the protein (10% SDS) 1 in 10 and make sure to have a final volume of 50µl. 
 Pipette 50µl of the standards and protein into 15ml tubes. 
 Add 250µl Reagent A to each tube and vortex. 
 Add 2ml Reagent B to each tube and vortex immediately. 
 Let the reaction proceed for 15 min. 
 After a few minutes have elapsed, transfer each sample to a cuvette. 
Read the absorbance at 750 nm and calculate the concentration using the standard curve 
(excel doc). 
6.3.5.2. Results 
Supernatant: 0.009 µg/µl 
Protein precipitate: 0.17 µg/µl 
6.4. In vitro reconstituted biosynthesis of ergothioneine in Mycobacteria smegmatis. 
Four sets of 500 µl reactions (1-4) containing 20 mM Tris HCl pH= 7.4, 20 mM NaCl , 0.2 
Mm FeSO4.7 H2O, 0.5 mM mercaptoethanol, 250 µl of crude enzymes and 50 mM of either 
(1) hercynyl cysteine thioeth r (28) (2) hercynyl cysteine sulfone (30) (3) deuterated 
hercynine (17) or (4) hercynyl cysteine methyl ester sulfoxide (26). The reaction was stopped 
by heating the mixture at 90°C for 2 min followed by lyophilisation. The crude enzyme 
reactions were incubated for 1 day at 37° C. The reaction was stopped by heating the mixture 
at 90°C for 2 min followed by lyophilisation and sunsequent reconstitution in LC buffer 
before analysis by LC/MS.  
Control  
Containing 250 µl of 20 mM Tris HCl pH = 7.4, 20 mM NaCl, 0.2 mM FeSO4.7 H2O, 0.5 

















6.5. HPLC –ESI/MS (QTOF) analysis. 
Analyses were carried out with a UHPLC Agilent 1290 Infinity Series (Germany), accurate 
mass spectrometer Agilent 6530 Qradrupole Time Of Flight (QTOF) equipped with an 
Agilent jet stream ionization source (positive ionization mode) (ESI+) and column (Eclipse + 
C18 RRHD 1.8 µm.2.1 X 50, Agilent, Germany). 
To optimise the MS signal, direct injection of 10 µl of standard solutions was dissolved in 3 
% acetonitrile, 0.1 % formic acid in milli-Q water. Analyte separation was attempted in 3 % 
acetonitrile, 0.1 % formic acid in milli-Q water as mobile phase in an isochratic flow rate of 
0.4 ml/min. 
The system was controlled with the software packages Mass Hunter workstation software 







































1. Trampota, M., United States Patent, 2010, US 7,767,826, B2. 
2. Garner, P.; Park , J-M., J. Org. Chem., 1987, 52, 2361. 
3. Health, H.; Lawson, A.; Rimington, C., J. Chem. Soc., 1951, 2215. 
4. Keheller, F. and Proinsias, O.K., Tetrahedron letters, 2007, 48, 4879. 
5. Mc Killop, A.;Taylor , R. J.K.; Watson, R.J.; Lewis, N., Synthesis , 1994, 31 
6. Crosignani, S.; White, P.D. and Linclau, B., J.org. Chem, 2004, 69, 5897. 
7. Collier, P.N.; Campbell, D.A.; Patel, I.; Raynham, T.M. and Taylor, R.J.K., J.Org. 
Chem., 2002, 67, 1802. 
8. Garner, P.; Park, J-M., Org. Syn. Coll, 1998, 9, 300. 
9. Bregant, S. and Tabor, A. B., J.Org. Chem., 2005, 70, 2430. 
10. Alsina, J.; Rabanal, F.; Chiva, C.; Giralt, E. and Albericio, F., Tetrahedron, 1998, 54, 
10125. 
11. Lidia, D.L.; Giampaolo, G., and Porcheddu, A., Org Lett, 2002, 4,553. 
12. Collier, P.N.; Campbell, D.A.; Patel, I.; Raynham, T.M. and Taylor, R.J.K., J.Org. 
Chem., 2002, 67, 1802. 
13. Reinhold, V.N; Ishikawa, Y. and Melville, D.B., J. Med. Chem, 1968, 11(2), 258. 
14. Cundy, D.; Gurr, P.A.; Knill, A.M., Arkivoc, 2000, 158. 
15. Halle, J.C. and Simonnin, M.P., J. Biol. Chem., 1981, 8569. 
16. Fattori, D.; Rossi, C.; Fincham, C.I.; Caciagli, V.; Catrambone, F. and Quartara, L., J. 
Med. Chem., 2007, 50, 550. 
17. Ishikawa, Y.; Israel, S.E. and Melville, D.B., J. Biol. Chem., 1974, 279, 4420. 
18. Navickas, V.; Ushakov, D. B.; Maier, M. E.; Stroebele, M. and Meyer, H-J, Org. Let., 
2010, 12, 3418. 
19. Kano, N., Daicho Y. and Kawashima, T., Org. Lett., 2006, 8, 4625. 
20. Erdelmeier, I.; Daunay, S.; Lebel, R.; Farescour, L. and Yadan, J.C., Green Chem., 2012, 
14, 2256. 
21. Erdelmeier, I., Patent WO2011/042480 A1, 2011. 
22. Arnaud, O.; Koubeissi, A.; Ettouati, L.; Terreux, R.; Alame, G.; Grenot, C.; Dumontet C.; 
Pietro, A.D.; Paris, J. and Falson, P., J. Med. Chem., 2010, 53, 6720. 
23. Ashraf, S. A., J. Basic Microbiol., 2010, 331. 
24. Ashraf, S. A., J. Microbiol., 2011,130. 
 
